

Medical Policy Bulletin

Title:

Treatments for Complex Regional Pain Syndrome (CRPS)

Policy #:

MA08.026o

The Company makes decisions on coverage based on the Centers for Medicare and Medicaid Services (CMS) regulations and guidance, benefit plan documents and contracts, and the member's medical history and condition. If CMS does not have a position addressing a service, the Company makes decisions based on Company Policy Bulletins. Benefits may vary based on contract, and individual member benefits must be verified. The Company determines medical necessity only if the benefit exists and no contract exclusions are applicable. Although the Medicare Advantage Policy Bulletin is consistent with Medicare's regulations and guidance, the Company's payment methodology may differ from Medicare.

When services can be administered in various settings, the Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member's medical needs and condition. This decision is based on the member's current medical condition and any required monitoring or additional services that may coincide with the delivery of this service.

This Policy Bulletin document describes the status of CMS coverage, medical terminology, and/or benefit plan documents and contracts at the time the document was developed. This Policy Bulletin will be reviewed regularly and be updated as Medicare changes their regulations and guidance, scientific and medical literature becomes available, and/or the benefit plan documents and/or contracts are changed.

Policy

Coverage is subject to the terms, conditions, and limitations of the member's Evidence of Coverage.

In the absence of coverage criteria from applicable Medicare statutes, regulations, NCDs, LCDs, CMS manuals, or other Medicare coverage documents, this policy uses internal coverage criteria developed by the Company in consideration of peer-reviewed medical literature, clinical practice guidelines, and/or regulatory status.

The Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member's medical needs and condition.

MEDICALLY NECESSARY

The following interventions are considered medically necessary, and, therefore, covered for treatment of complex regional pain syndrome (CRPS) when their respective criteria are met:

- Local anesthetic sympathetic nerve blocks (i.e., stellate ganglion block for upper extremity pain or lumbar sympathetic block for lower extremity pain) related to CRPS when first-line pain management strategies (e.g., oral medications [e.g., nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioids, antiepileptics, antidepressants, clonidine, muscle relaxants], physical therapy, or occupational therapy) tried for at least a 2-week period have failed to diminish or eliminate the individual's pain.
 - Following a positive response to the initial diagnostic stellate ganglion block, and sustained benefit in pain and function after three sympathetic blocks from baseline (preblock) pain and function; additional regional sympathetic blocks of up to a maximum of six total blocks in a 12-month period performed at a frequency of no more than two per week, are considered medically necessary, and, therefore, covered when all the following criteria have been met:
 - Benefit has been demonstrated by prior blocks as evidenced by all of the following:
 - Decreased use of pain medication

- Improved level of function (e.g., increased range of motion, strength, and use of extremity in activities of daily living)
 - Improved tolerance to touch (e.g., decreased allodynia) or other objective measures
 - 80% reduction in pain for at least the duration of the injected local anesthetic
 - A rise in temperature of at least 2 degrees Celsius from baseline of the ipsilateral limb
- The intervention is being provided as part of a comprehensive pain management program (physical therapy, patient education, psychosocial support, and oral medication).
- Epidural or intrathecal (IT) opioids: A preliminary trial of opioid drug administration for the treatment of severe, chronic, intractable pain via a temporary IT/epidural catheter is indicated for individuals who are unresponsive to less-invasive medical therapy such as orally administered systemic opioids and/or nerve blocks with local anesthetics and steroids.
 - If this preliminary trial demonstrates pain relief and a degree of side effects that are adequately acceptable (including effects on activities of daily living) and has the individual's acceptance, a permanent implantable infusion pump may be considered for continuous IT or epidural administration of opioids.
 - The drug being administered and the purpose of its administration must be consistent with the indicated uses in the pump's US Food and Drug Administration (FDA)–approved labeling.
 - The individual has a life expectancy of at least 3 months.
- IT ziconotide (Prialt®): The administration of IT ziconotide (Prialt®) is indicated for the management of severe chronic pain in individuals for whom IT therapy is warranted and who are intolerant of, or refractory to, other treatments such as systemic analgesics (e.g., NSAIDs, opioids, antiepileptics, antidepressants) adjunctive therapies (e.g., physical therapy, nerve blocks, spinal cord stimulation), or IT morphine.
- Intrathecal baclofen: A preliminary trial of IT baclofen is indicated when pain is due to spasticity for individuals who are unresponsive to, or intolerant of, at least a 6-week trial of noninvasive medical therapy, such as orally administered antispasmodic drugs.
 - If this preliminary trial demonstrates pain relief and a degree of side effects that are adequately acceptable (including effects on activities of daily living) and has the individual's acceptance, a permanent implantable infusion pump may be considered for continuous IT or epidural administration of opioids.
 - The drug being administered and the purpose of its administration must be consistent with the indicated uses in the pump's FDA-approved labeling.

EXPERIMENTAL/INVESTIGATIONAL

All other interventions are considered experimental/investigational and, therefore, not covered, for the treatment of CRPS because their safety and/or effectiveness cannot be established by review of the available published peer-reviewed literature (not an all-inclusive list):

- Chemical sympathectomy
- Continuous peripheral nerve block with any drug
- Epidural clonidine
- Intramuscular botulinum toxin
- Intramuscular ketamine
- Intramuscular magnesium sulfate
- IT clonidine
- IT glycine
- IT methylprednisolone
- IT opioids in combination with bupivacaine or lidocaine
- Intrathoracic administration of analgesics
- Intravenous (IV) regional sympathetic nerve block (IVRB) with any drug (e.g., bretylium, guanethidine, ketamine, ketanserin, lidocaine, phenoxybenzamine, reserpine)
- IV (systemic) administration with any of the following agents:
 - IV bisphosphonates
 - IV bupivacaine
 - IV dexmedetomidine
 - IV dimethylsulfoxide (DMSO)
 - IV immunoglobulin G (IVIG)

- IV ketamine
- IV lidocaine
- IV magnesium
- IV mannitol
- IV opioids
- Plasma exchange
- Plasmapheresis
- Cervical plexus catheter nerve block with any drug
- Brachial plexus catheter nerve block with any drug
- Lumbar plexus catheter nerve block with any drug
- Sacral plexus catheter nerve block with any drug

REQUIRED DOCUMENTATION

The individual's medical record must reflect the medical necessity of the care provided. These medical records may include, but are not limited to: records from the professional provider's office, hospital, nursing home, home health agencies, therapies, and test reports.

The Company may conduct reviews and audits of services to our members, regardless of the participation status of the provider. All documentation is to be available to the Company upon request. Failure to produce the requested information may result in a denial for the drug.

BILLING REQUIREMENTS

Inclusion of a code in this policy does not imply reimbursement. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

If there is no specific Healthcare Common Procedure Coding System (HCPCS) code available for the drug administered, then the drug must be reported with the most appropriate unlisted code along with the corresponding National Drug Code (NDC).

Guidelines

- Ziconotide (Prialt®); epidural infusions of opioids; intrathecal (IT) infusions of opioids and baclofen by implantable pumps:
 - This policy is consistent with Medicare's coverage criteria.
- Intravenous (IV) regional sympathetic nerve block and systemic administration via the IV route, and intrathoracic administration of opioids and nonopioids
 - There are no Medicare coverage determinations addressing these services; therefore, the Company policy is applicable.

BENEFIT APPLICATION

Subject to the terms and conditions of the applicable Evidence of Coverage, certain parenteral treatments for complex regional pain syndrome are covered under the medical benefits of the Company's Medicare Advantage products when medical necessity criteria in this medical policy are met.

Drugs that are experimental/investigational are excluded for the Company's Medicare Advantage plans because they are not covered by Medicare. Therefore, they are not eligible for reimbursement consideration.

ADMINISTRATION

IT ziconotide (Prialt®) is intended for use only in the Medtronic SynchroMed® II Infusion System, and the CADD-Micro Ambulatory Infusion Pump; it is not intended for IV or epidural administration.

Description

A number of parenterally administered drugs have been promoted for the treatment of complex regional pain syndrome (CRPS), formerly known as reflex sympathetic dystrophy (RSD) and sometimes designated as RSD/CRPS. This disorder has also been called posttraumatic dystrophy, causalgia, minor causalgia, Sudeck's atrophy, and shoulder-hand syndrome. CRPS is a chronic, regional, posttraumatic pain syndrome with abnormalities in the sensory, motor, and autonomic nervous systems that typically develops some time after an acute injury to a joint or limb. However, CRPS may occur with no obvious precipitating event, or it may emerge in nontraumatized parts of the body.

Considerable confusion and controversy exist regarding the terminology, diagnosis, and treatment of CRPS. This is due in part to the recent explosion of information on the subject of posttraumatic limb pain in general. Currently, most pain experts adhere to the terminology for CRPS that was developed by the International Association for the Study of Pain (IASP; Merskey and Bogduk, 1994; Stanton-Hicks et al, 1995), which deliberately avoids suggesting the etiology or the site.

There are two types of CRPS, each with identical clinical features. Type 1 CRPS follows an illness or injury that has not directly damaged the affected limb. Type 2, once termed causalgia, occurs in individuals who have had a major peripheral nerve injury (International Association for the Study of Pain Diagnostic Criteria).

DIAGNOSIS OF CRPS

There are no universally accepted diagnostic criteria for CRPS (Harden, 2001), nor is there a single diagnostic test that identifies it. Moreover, diagnosing CRPS is difficult because the condition is associated with a variety of clinical features, temporal factors, vascular and musculoskeletal phenomena, and underlying causes (Schott, 2001).

Although a variety of diagnostic criteria for CRPS has been proposed, most authorities agree that the diagnosis of CRPS should be based on history of injury, the individual's complaints, and physical signs (Atkins, 2003; Harden, 2001).

Following are the IASP Diagnostic Criteria for Type 1 and Type 2 CRPS (adapted from Merskey and Bogduk, 1994, and Harden, 2013):

- **Type 1 CRPS**
 - Continuing pain, allodynia, or hyperalgesia in which the pain is out of proportion to the initiating event;
 - Evidence of edema, changes in skin blood flow, or abnormal sudomotor activity in the painful region (this criterion is satisfied by either a sign or a symptom); and
 - No other condition that would account for the degree of pain and dysfunction.
- **Type 2 CRPS**
 - Type 2 CRPS is diagnosed when, in addition to the above three criteria for CRPS type 1, there is also an initiating noxious event or a cause of immobilization.

Following are the clinical diagnostic criteria for CRPS (adapted from Harden, 2013):

- Continuing pain, which is disproportionate to any inciting event
- At least one symptom in three of the four following categories, AND at least one sign* at time of evaluation in two or more of the following categories:
 - Sensory: Reports/evidence of hyperalgesia and/or allodynia
 - Vasomotor: Reports/evidence of temperature asymmetry and/or skin color changes and/or skin color asymmetry
 - Sudomotor/Edema: Reports/evidence of edema and/or sweating changes and/or sweating asymmetry
- Motor/trophic: Reports/evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin)
- No other diagnosis that better explains the signs and symptoms

*A sign is counted only if it is observed at time of diagnosis.

TERMS RELATED TO COMPLEX REGIONAL PAIN SYNDROME

- **Allodynia:** perception of pain with an ordinarily nonpainful stimulus (e.g., air or clothing)
- **Hyperalgesia:** increased sensitivity to noxious stimulation
- **Hyperesthesia:** lowered pain threshold that permits increased pain from typically noxious stimulation
- **Neuropathic:** pertaining to injury to the peripheral or central nervous system
- **Nociceptive:** pertaining to damage to tissues due to thermal, chemical, mechanical, or other types of irritants and sensed by nociceptors
- **Sudomotor:** pertaining to stimulation of the sweat glands
- **Vasomotor:** pertaining to nerves supplying muscles in the walls of blood vessels

DISTINCTION BETWEEN CRPS-TYPE PAIN AND NOCICEPTIVE PAIN

CRPS is part of a broader classification of disorders called neuropathic pain disorders, which include postherpetic neuralgia (PHN), painful diabetic neuropathy (PDN), and central poststroke pain syndrome. The neuropathic pain disorders comprise a complex group of disorders with many signs and symptoms that vary in number and intensity over time. Neuropathic pain disorders are related to dysfunction or disease of the nervous system at a peripheral level, a central level, or both, whereas the more commonly understood nociceptive pain is caused by the activation of pain receptors (nociceptors). Thus, neuropathic pain in general, and CRPS pain in particular, differ fundamentally in etiology from the pain in nociceptive pain disorders. Chronic neuropathic pain (including CRPS) develops as a result of injury that somehow leads to abnormalities in transmission within the peripheral and/or central nervous system (Dworkin et al., 2003). More specifically—and for poorly understood reasons—CRPS pain develops as a result of reorganization within the nervous system. One outcome of this reorganization is a lowered threshold to nociceptive processing, as well as distorted pain perceptions. For example, individuals with chronic neuropathic pain syndromes such as CRPS may have pain in response to stimuli that are normally not painful (allodynia) or they may have exaggerated pain in response to stimuli that are normally less painful (hyperalgesia). Also, individuals with neuropathic pain of the CRPS type may experience pain even in the absence of stimuli. It is believed that many of the symptoms found in CRPS, such as allodynia or hyperalgesia, reflect a more easily excited nervous system that promotes pain sensation (Argoff, 2002).

EPIDEMIOLOGY

The variety of diagnostic criteria that have been used for CRPS has contributed to uncertainty regarding the exact incidence of CRPS. It has been estimated that CRPS occurs in approximately one of every 2000 traumatic events (Subbarao and Stillwell, 1981). CRPS affects both genders and all ages (including children). The disorder appears to be more common between the ages of 40 and 60 and may be more frequent in women. Genetic factors may play a role (Kimura et al., 2000; Devor and Raber, 1990; Mailis and Wade, 2001).

ETIOLOGY

The exact cause of CRPS is poorly understood. Its development is sometimes preceded by diseases of the peripheral and central nervous system, such as stroke, multiple sclerosis, spinal trauma, and shingles. Systemic diseases associated with CRPS include myocardial infarction, cardiac surgery, and drugs. Although there is no single specific etiology of CRPS, it is agreed that its most common antecedent is trauma. Bonica (1979) and Veldman et al. (1993), using the definition of RSD, reported on a study that found that 65% of CRPS cases followed trauma (mostly a fracture); 19% followed an operation; and 2% followed an inflammatory process. In 4% of cases, onset of symptoms followed various other precipitating factors, such as injection, intravenous infusion, or cerebrovascular accident. In 10% of cases, no precipitant could be identified. CRPS type 2 (causalgia) has been reported after automated laser discectomy and cervical epidural injection.

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE “STATE OF THE SCIENCE” WORKSHOP SUMMARY

The National Institute of Neurological Disorders and Stroke and the National Institute of Health (NIH) Office of Rare Diseases (NINDS, 2015) reviewed the status of current research on CRPS/RSD and concluded that 1) RSD/CRPS appears to be a disease of the central nervous system, 2) there is little evidence upon which to base a choice of therapy for CRPS, and 3) there is an urgent need for many of these therapies to be tested in appropriately designed prospective clinical trials. This need is most urgent in the following areas: a) diagnostic criteria, b) epidemiology, c)

CRPS model systems, d) disease mechanisms, e) integration between basic research and clinical research, and f) therapy (NINDS, 2015).

TREATMENT IN GENERAL

Because of the heterogeneity of neuropathic pain disorders and the lack of knowledge about their underlying causes, progress in developing reliable treatments for neuropathic pain disorders in general has proceeded very slowly. The same can be said of CRPS in particular. Most authorities recommend aggressive treatment in the early stages of CRPS, reasoning that the earlier treatment is instituted, the greater the likelihood that symptom progression will be contained (Schwartzmann, 2000). Individuals first presenting with moderate pain are more likely to have pain improvement or resolution than those presenting with severe pain. Delay in treatment prolongs rehabilitation. Without treatment, permanent tissue damage, chronic pain, and impairment are likely (Atkins, 2003).

Currently, initial treatment of CRPS consists of reassurance, excellent analgesia, and intensive, careful physiotherapy to minimize pain and avoid disuse of the affected limb (Stanton-Hicks, 1998). CRPS responds poorly to traditional treatments and to usual doses of analgesics. Nonsteroidal anti-inflammatory drugs may be more effective than opiates. Individuals who do not respond rapidly to these agents should be evaluated by a pain specialist for consideration of second-line treatment with drugs. However, drug therapy is often unsuccessful (Harden, 2001; Stanton-Hicks, 1998). Various drugs have been used in CRPS to accomplish sympathetic nerve block—by means of either intravenous regional block (IVRB) or direct block of ganglia, as occurs in brachial plexus, stellate ganglion (i.e., cervical), and lumbar-blocking procedures. Also, some authorities advocate using permanent sympathectomy when sympathetic nerve blocks no longer prove effective. Other interventions include desensitization of peripheral nerve receptors with capsaicin and nerve root stimulation by either transcutaneous or implanted dorsal column stimulator methods. Again, no treatment method has proved itself to be reliably effective over time, and claims of benefit remain unconfirmed (Kingery, 1997; Harden, 2001).

A meta-analysis to assess which agent should be prioritized when designing a therapeutic regimen was performed by Vertli et al (2014). They found bisphosphonates, *N*-Methyl-D-aspartate (NMDA) receptor analogues, and vasodilators showed better long-term pain reduction than placebo. The authors note the lack of available well-designed studies. In their analysis there were insufficient data from which to analyze effect on disability.

In 2015, Zernikow et al. reviewed the literature to assess current evidence on the effectiveness of invasive treatments for CRPS in 173 children and adolescents. The invasive treatments applied most often were singular sympathetic blocks, epidural catheters, and continuous sympathetic blocks. Individuals frequently received more than one invasive procedure. The authors noted the lack of methodological quality in the studies, and found that outcomes were rarely evaluated using validated measures. Consequently, they concluded that the level of evidence for invasive therapies in the treatment of CRPS in children and adolescents is weak.

According to NINDS, parenteral nonopioid treatment options include sympathetic nerve block, botulinum toxin injections, and NMDA receptor antagonists (such as dextromethorphan and ketamine). However, the NINDS notes that no single drug or combination of drugs is guaranteed to be effective in every individual, and no drug has been approved by the FDA specifically for CRPS. According to the NINDS, no studies of intrathecal drug pumps with clonidine or baclofen have shown benefit for CRPS. Intravenous immunoglobulin and ketamine are still considered “emerging treatments” (NINDS, 2015).

Noting that there are few clinical guidelines for using IV therapies to treat CRPS, Xu et al. conducted a systematic review of the literature that focused specifically on IV therapy (2016). The search strategy yielded 299 articles of which 101 were deemed relevant and 63 were retrieved for analysis. The authors addressed IV bisphosphonates, IV immunoglobulin, IV ketamine, IV magnesium, IV mannitol, IV regional blocks and IV anti-tumor necrosis factor (TNF) antibodies. They recommended the following: IV bisphosphonates to reduce pain associated with bone loss in individuals with CRPS type I, IV immunoglobulin for refractory pain cases, IV ketamine in some refractory individuals, IVRB with ketorolac (when used with lidocaine) for short-term pain reduction, and IVRB lidocaine at 5 mg/kg/h for reducing thermal pain. In recommending that bisphosphonates can be used to reduce pain associated with bone loss in individuals with CRPS, the authors found evidence level 1B+ (four references) and 2C+ (two references). All references have been previously reviewed in this document with the exception of a letter to the editor. The recommendation for IV immunoglobulin (2B+/2C+) was based on work by Goebel et al. (also previously reviewed in this document). The ketamine recommendation (2B+/2C+) was based on studies also previously reviewed in this document. Many of the same ketamine studies were reported multiple times by different authors in different journals. IVRB with ketorolac (when used with lidocaine) was recommended (level of evidence 2B+/2C+) based on studies (other than animal reports and case studies) previously reviewed. While recommending these treatments, the authors indicate that most studies of IV therapies for CRPS are not high quality, and further studies of RCT quality are required. It is not known if the recommended drugs are useful for acuity or chronicity. The authors

found the following to lack sufficient evidence or were studied in trials that yielded conflicting results: IV magnesium (2B+), IVRB with clonidine, phenoxymethamine or labetalol (2C+). Not recommended were the following: IV methylprednisolone and parecoxib (2B-/2C+), IV mannitol (2B-), IVRB with guanethidine, reserpine or droperidol (2A-/2B-), IV TNF- α antibodies (2B-).

Kim et al. (2016) noted that although reviews suggest that physical and occupational therapy, bisphosphonates, calcitonin, sub-anesthetic intravenous ketamine, free radical scavengers, oral corticosteroids, and spinal cord stimulation may be effective treatments of CRPS, there is a lack of high-quality evidence to support the efficacy of the most commonly used interventions.

According to Gatti et al. (2016), the few studies available regarding CRPS treatments are too small to be conclusive. However, they suggest that on the basis of the results of a few RCTs, high doses of bisphosphonates should be considered the treatment of choice for individuals with CRPS type 1.

A review by authors from Massachusetts General Hospital observed that evidence of efficacy of CRPS treatment is strongest for rehabilitation therapies including graded motor imagery, neuropathic pain medications, and electric stimulation of the spinal cord, injured nerve or motor cortex. Investigational treatments include ketamine, botulinum toxin, immunoglobulins, and transcranial neuromodulation (Oaklander and Horowitz, 2015).

The same conclusion regarding botulinum toxin was reached by Oh and Chung (2015) after a review. Additionally, an opinion piece from Case Western, the University of Pennsylvania, and Yale concluded that botulinum toxin for treatment of CRPS is preliminary and awaits RCT results (Mittal et al., 2016). A randomized trial for low-dose intravenous immunoglobulin treatment for long-standing CRPS concluded that low-dose immunoglobulin treatment for 6 weeks was not effective in relieving pain in individuals with moderate to severe CRPS of 1 to 5 years' duration (Gobel et al., 2018).

An review by Abdi (2016) notes that there is some support for bisphosphonates for CRPS including IV alendronate, IV neridronate, IV pamidronate, and IV clodronate. Calcitonin is also a drug that has been studied for CRPS. However, of three trials, only one found benefit. Only low to moderate evidence is available to support using ketamine as a CRPS treatment, and there is a need for further trials to assess the efficacy of IVIG. According to Abdi, the limited evidence base for regional sympathetic nerve block and epidural clonidine suggests no benefit from these procedures.

The role of surgery in CRPS is limited.

PEDIATRIC TREATMENT

A review of treatments for pediatric CRPS noted that when there is a response to ketamine treatment, the duration of its effect can be limited from a few weeks to two months (Weissman and Uziel, 2016). While a few noncontrolled reports support use of bisphosphonates in the early stages, the authors concluded that to date, no specific pharmacological treatments are recommended for pediatric CRPS, and no large clinical trials are being conducted. The most commonly used invasive treatments in pediatric CRPS are single sympathetic blocks, epidural catheters, and continuous sympathetic blocks. However, the authors also indicate that there is a weak level of evidence for the use of invasive treatments in the pediatric population, and no large prospective blinded controlled trials are available.

According to Williams and Howard (2016), while interest in the use of intravenous therapies for CRPS treatment in children has increased (bisphosphonates in the presence of bone loss or demineralization) the evidence of efficacy for intravenous therapies is weak and further evaluation in terms of long-term efficacy, risks, and cost effectiveness needs to be explored. The authors note the concern for short-term and long-term neuropsychiatric effects of using ketamine along with studies that suggest long-term pain reduction may not be sustained. Other intravenous agents including magnesium, free radical scavengers (mannitol), anti-inflammatory agents, local anesthetics, drugs acting on the sympathetic nervous system (guanethidine, reserpine, phenoxymethamine, beta blockers, and anti-TNF antibodies (infliximab) have not been tested in RCTs. Efficacy of intravenous regional blockage is not proven. Evidence of interventional modalities including peripheral nerve catheters and epidural blockade in children and adolescents is weak.

After a review of the literature of invasive modalities for pediatric CRPS, Rodriguez et al. (2015) found no RCTs that compared conservative and invasive management in children. The paucity of data, lack of randomized trials, and lack of quality evidence led the authors to conclude that interventional treatments for CRPS in children should be provided only in clinical research settings that have the experience and ability to report the outcomes.

SYMPATHETIC NERVE BLOCKS (STELLATE GANGLION BLOCK AND LUMBAR SYMPATHETIC BLOCK)

Freedman et al. (2014) reviewed interventional treatments, including sympathetic blockade, and found that they are most beneficial in individuals who demonstrate sympathetically mediated symptoms and those whose pain is limiting participation in therapy.

The efficacy of local anesthetic sympathetic blocks is a subject of controversy, and reviewers have noted that the quality of evidence on lumbar and stellate blocks is poor (Nelson and Stacey, 2006; Albazaz et al., 2008; Cepeda et al., 2005; Harden et al., 2013). However, it is also noted that local anesthetic blocks have been used for many years to treat CRPS. Van Eijs et al. (2011) considered sympathetic block to be the interventional treatment of first choice, but O'Connell et al. (2013), in a comprehensive review, found low-quality evidence that sympathetic nerve blocks with anesthetic is not effective. Reviewers find that results may depend on early application before central pain pathways can set in (Nelson and Stacey, 2006; Albazaz et al., 2008). In addition, uncontrolled surveys in the literature note that approximately 70% of individuals report full or partial responses (Wheeler 2010).

The Colorado Division of Workers' Compensation's medical treatment guidelines on "Complex regional pain syndrome/reflex sympathetic dystrophy" (2011) noted that "Sympathetic injections are generally accepted, well-established procedures. They include stellate ganglion blocks and lumbar sympathetic blocks. Unfortunately, there are no high quality randomized controlled trials in this area."

The Washington State Department of Labor and Industries' guidelines on "Work-related complex regional pain syndrome (CRPS): Diagnosis and treatment" (2011) stated that "Sympathetic blocks have long been a standard treatment for CRPS and can be useful for a subset of cases. Stellate ganglion blocks (cervical sympathetic blocks) and lumbar sympathetic blocks are widely used in the management of upper and lower extremity CRPS. There is limited evidence to confirm effectiveness. An initial trial of up to three sympathetic blocks should be considered when the condition fails to improve with conservative treatment, including analgesia and physical therapy."

An UpToDate review on "Prevention and management of complex regional pain syndrome in adults" (Abdi, 2014) states that "Local sympathetic blocks (e.g., stellate ganglion block) with local anesthetic, while of unproven benefit in terms of the long-term outcome, nevertheless may provide a short-term decrease in pain that can be diagnostically useful and that can help with mobilization of the affected limb. The author has experience in using clonidine in combination with local anesthetics for stellate ganglion and lumbar sympathetic nerve blocks successfully, but its value needs to be systematically studied. Stellate ganglion blocks may be performed at one week intervals and may be repeated several times. This treatment is abandoned if an immediate response (e.g., improved temperature and decreased pain) does not occur following the first or second nerve block."

In an opinion article, Resmini et al. (2016) noted that sympathetic nerve blocks are commonly indicated despite lack of efficacy in current literature. There are no guidelines that define what medications should be administered for CRPS treatment, but several drugs have been used, despite lack of scientific evidence supporting their use. This list of drugs includes anti-inflammatory drugs, analgesics, anesthetics, anticonvulsants, antidepressants, corticosteroids, calcitonin, bisphosphonates, and calcium channel blockers. While noting the lack of evidence for bisphosphonates, the authors suggest that neridronate is associated with clinically relevant and persistent benefits in CRPS individuals. Moreover, the use of bisphosphonates as first-line drug treatment is advocated by these researchers. It should be noted that neither neridronate nor other bisphosphates are approved by the FDA to treat CRPS. A clinical trial is ongoing for neridronate in CRPS-1 (Clinicaltrials.gov).

Chemical sympathectomy is a procedure in which phenol or alcohol is injected to destroy the sympathetic chain. The outcomes of trials are variable, with questionable efficacy. In concluding that there is poor evidence for the long-term effectiveness of this modality, the authors cited a Cochrane review that also concluded that sympathectomy should be used cautiously in selected individuals and only after failure of other treatment options (Straube et al., 2013).

PLEXUS CATHETER NERVE BLOCK AND CONTINUOUS PERIPHERAL NERVE BLOCK

According to Harden et al. (2013), preoperative posttrauma, postoperative pain relief, and intractable pain of CRPS types 1 and 2 are indications for brachial plexus blockade. Van Eijs et al. (2011) recommend plexus brachialis blocks for individuals refractory to conventional treatment. Related to plexus catheter nerve blocks are continuous peripheral nerve blocks (CPNBs), also known as perineural local anesthetic infusion. CPNBs are indicated for prolonging intraoperative anesthesia and treating intractable hiccups. Although some have suggested that these blocks may be effective treatment of CRPS (Aquirre et al., 2012), this indication has, as yet, not been validated through well-designed studies (Ilfeld, 2011).

INTRAVENOUS REGIONAL SYMPATHETIC NERVE BLOCKADE (IVRB) IN GENERAL

Intravenous regional sympathetic nerve blockade (IVRB) in CRPS is intended to confine and concentrate medication at the sympathetic nerve endings in a particular region to produce sympathetic denervation without interrupting motor activity (Brown, 1997). Frequent or chronic use of the various agents recommended in IVRB has never been supported in the scientific literature (Stanton-Hicks 1998), although Harden (2001) suggests that a short trial of a limited number of nerve blocks with very clear goals and time limitations may be indicated for ethical reasons, and may be cost-effective if attempts at functional restoration are unsuccessful. In any event, the timing of IVRB should be guided by the need for functional restoration (Stanton-Hicks et al., 1998). For example, failure to progress in 2 to 4 weeks with a combination of reactivation, contrast baths, and desensitization to the next level of flexibility exercises, edema control, peripheral E-stimulation, and isometric strengthening should prompt consideration of introducing the most aggressive therapies, such as intravenous regional sympathetic blocks, psychotherapy, and/or pharmacotherapy (Stanton-Hicks et al., 1998). Few studies support the use of other agents in IVRB (atropine, bretylium, phentolamine, clonidine, guanethidine, parecoxib, reserpine, droperidol with heparin, lidocaine, methylprednisolone with lidocaine, ketorolac, ketanserin), alone or in combination (Harden et al., 2013; O'Connell et al., 2013; Goebel et al., 2012; Abdi, 2014; Freedman et al, 2014).

SPECIFIC AGENTS PROPOSED FOR IVRB

INTRAVENOUS BRETYLIUM TOSYLATE IN IVRB

Bretylium tosylate had been promoted as an IVRB adrenergic blocking agent. However, it has not been approved by the FDA for use in CRPS. Moreover, although it was once available for other indications, injectable bretylium is no longer available in the United States. Previously, intravenous bretylium in combination with lidocaine in IVRB significantly reduced pain compared with lidocaine alone in one randomized crossover, controlled study involving 12 individuals (Hord et al., 1995). No other trials involving bretylium in CRPS were identified in this assessment.

INTRAVENOUS BUPIVACAINE IN IVRB

A search of the medical literature revealed a single low-quality study of bupivacaine in subjects diagnosed with RSD (Bonelli et al., 1983). The study found no difference between stellate ganglion block via bupivacaine and regional intravenous block via guanethidine. In 2012, a pilot study by Toshniwal et al. randomly assigned 33 individuals to either continuous stellate ganglion (CSG) block or continuous infraclavicular brachial plexus block (CIPB) for the management of CRPS type 1 of the upper extremity. Bupivacaine 0.125% was infused for 1 week, after which the individuals were followed for 4 weeks. The CIPB group showed significant improvement compared with the CSG group during the first 12 hours after the infusions. After 12 hours, the pain score was similar between the groups. At 4 weeks, both groups showed significant improvement in edema and ROM scores, which led the authors to recommend a larger, well-randomized, well-controlled clinical trial to confirm the findings. Therefore, evidence that intravenous bupivacaine improves the net health outcome is lacking. Furthermore, the FDA has not approved its use in CRPS.

INTRAVENOUS GUANETHIDINE IN IVRB

Guanethidine is a postadrenergic blocking agent that has been promoted for IVRB in CRPS. However, its use in CRPS has not been approved by the FDA. Guanethidine alone, during an attempt to achieve IVRB, produced no benefit over placebo in an RCT involving 16 individuals (Jadad et al., 1995). In a cross-over RCT, Ramamurthy and Hoffman (1995) found no significant differences from intravenous guanethidine alone or in combination with lidocaine. In a low-quality crossover study (Rocco et al., 1989) (12 individuals), no difference in pain reduction between intravenously administered guanethidine plus lidocaine, reserpine plus lidocaine, or lidocaine alone was found. An RCT performed by Gschwind et al. (1995) in 71 individuals undergoing fasciectomy for Dupuytren's disease resulted in preoperative intravenous guanethidine showing no advantage over placebo in the prevention of CRPS. In addition, most guanethidine trials have failed to show improvement in efficacy over lidocaine or saline. O'Connell et al. (2013) found moderate-quality evidence that IVRB using guanethidine is not effective and may be associated with complications. A review by Rockett (2014) observes that intravenous regional anesthesia or intravenous regional block (IVRA or IVRB) with guanethidine is no longer recommended due to significant adverse effects. In summary, for intravenous guanethidine in CRPS, there is limited evidence suggesting that it does not improve the net health outcome. In addition, intravenous guanethidine has not received FDA approval for use in CRPS.

INTRAVENOUS KETAMINE IN IVRB

Ketamine, a drug well known for its ability to induce dissociation during anesthesia, has been proposed in IVRB in the treatment for CRPS. The agent has been reported to reduce continuous and evoked pain when given in prolonged and low doses in individuals with injury of the peripheral and central nervous system (Correll et al., 2002; Eide et al., 1995). A search of the medical literature produced no RCTs involving the use of intravenous ketamine in CRPS. Existing studies investigating ketamine are of poor quality or address only non-CRPS pain. Therefore, intravenous ketamine in CRPS has not been shown to improve the net health outcome. In addition, intravenous ketamine has not been approved by the FDA for use in CRPS.

INTRAVENOUS KETANSERIN IN IVRB

Two RCT studies investigated intravenous ketanserin (a selective serotonin receptor antagonist with weak adrenergic receptor–blocking properties) against placebo to achieve regional sympathetic blockade. A study by Hanna and Peat (1989) found a significant improvement in pain in individuals diagnosed with RSD who were receiving 10 mg of ketanserin in a single bolus. The other study involving ketanserin (Bounameaux et al., 1984) showed no difference in pain reduction with ketanserin compared with placebo. For intravenous ketanserin in CRPS, there is inadequate evidence upon which to make conclusions regarding health outcomes. Intravenous ketanserin is not available outside investigational settings, and it has not been approved by the FDA for use in CRPS.

INTRAVENOUS LIDOCAINE IN IVRB

Lidocaine hydrochloride is used during IVRB as a local anesthetic and sometimes with other injectable medications such as a diluent solution providing local anesthesia. An RCT involving seven individuals diagnosed with CRPS type 1 (Price et al., 1998) showed intravenous lidocaine administered to achieve an IVRB resulted in a slight improvement when compared with saline. The improvement was not significant, however. In a low-quality crossover study (Rocco et al., 1989) (12 individuals), no difference in pain reduction between intravenously administered guanethidine plus lidocaine, reserpine plus lidocaine, or lidocaine alone was found.

A systematic review (Challapalli et al., 2005) of the analgesic effect of lidocaine and its oral analogues found that these agents were safe in controlled clinical trials for neuropathic pain, were better than placebo, and were as effective as other analgesics. However, these results are limited by the few trials with adequate information on safety and efficacy, and by the heterogeneity of the model. A retrospective study of IVRB with lidocaine and methylprednisolone for treatment of upper extremity CRPS in 168 individuals was conducted in Greece by Varitimidis et al. (2011). According to the authors, after a mean follow-up of 5 years, a complete absence of pain was reported by 92% of individuals. They noted that treatment must start early to expect such good results. As with other nonrandomized, uncontrolled studies, the placebo effect cannot be discounted in this report. Eckmann et al. (2011) reported the results of a randomized, double-blinded, crossover study of lidocaine with ketamine in CRPS of the lower extremity in 10 adults; only one individual achieved significant improvement. In addition, Goebel et al. (2012) found evidence to be conflicting for lidocaine sympathetic ganglion blocks. Therefore, for intravenous lidocaine in CRPS, there is limited evidence to suggest that it does not improve the net health outcome. Lidocaine has not been approved by the FDA for use in CRPS.

INTRAVENOUS PARECOXIB IN IVRB

Intravenous parecoxib is the only injectable COX-2 inhibitor. It is widely used in Europe under the brand name Dynastat. In a randomized placebo-controlled double-blind trial, neither pressure pain threshold nor quantitative sensory testing was improved with the drug (Breuer et al., 2014). The FDA declined to approve parecoxib for use in the United States in 2005. The lack of scientific evidence does not permit conclusions regarding net health outcomes.

INTRAVENOUS PHENOXYBENZAMINE IN IVRB

Because oral phenoxybenzamine and other oral alpha-adrenergic blocking agents have been used with varying degrees of success in CRPS, there has been speculation that phenoxybenzamine could be used as an IVRB agent in CRPS. The agent has not been approved by the FDA for use in CRPS (Malik et al., 1998). A search of the medical literature produced no RCTs involving the use of intravenous phenoxybenzamine in CRPS. Therefore, evidence upon which to base conclusions regarding the use of phenoxybenzamine in IVRB is lacking. The use of phenoxybenzamine in CRPS has not been shown to improve the net health outcome.

INTRAVENOUS PHENTOLAMINE IN IVRB

A high-quality study (Verdugo and Ochoa, 1994) (77 individuals) showed that 30 minutes of 35 mg of intravenous phentolamine for the treatment of “reflex sympathetic dystrophy” was ineffective. Therefore, for intravenous phentolamine in CRPS, there is limited evidence upon which to base a conclusion (Kosharskyy et al., 2013). That evidence suggests that intravenous phentolamine does not improve the net health outcome. Therefore, intravenous phentolamine in CRPS has not been shown to be as beneficial as any established alternatives. According to Wheeler 2014, controlled clinical trials of IV phentolamine showed mixed results and are hampered by poor methodology. Intravenous phentolamine is available outside investigational settings; however, it has not been approved by the FDA for use in CRPS.

INTRAVENOUS PHENYLEPHRINE IN IVRB

In an RCT by Verdugo and Ochoa (1994), phenylephrine given during IVRB for the treatment of “reflex sympathetic dystrophy” was ineffective. Accordingly, for intravenous phenylephrine in CRPS, there is limited evidence suggesting that it does not improve the net health outcome. Therefore, intravenous phenylephrine in CRPS has not been shown to be as beneficial as any established alternatives. Intravenous phenylephrine is available outside investigational settings; however, it has not been approved by the FDA for use in CRPS.

INTRAVENOUS RESERPINE IN IVRB

Intravenous reserpine combined with intravenous guanethidine to achieve regional sympathetic blockade gave no benefit over placebo in one RCT (Blanchard et al., 1990). For intravenous reserpine in CRPS, there is limited evidence suggesting that it does not improve the net health outcome. Intravenous reserpine has not been approved for use in CRPS.

SYSTEMIC INTRAVENOUS AGENTS IN GENERAL

In 2015, Casale et al. comprehensively reviewed currently available systemic drug treatments for CRPS. The authors indicate that over the last few decades, a large number of drugs have been proposed for systemic administration. However, due to the lack of RCTs, this approach to treatment remains empirical. Although corticosteroids are often the first agents to be employed, they continue to be controversial. According to these authors, good results have been obtained using dexamethasone and mannitol. However, neither of these agents have been FDA approved for CRPS treatment. The NMDA receptor antagonists (ketamine, amantadine, memantine, dextromethorphan [DM] and methadone) need additional clinical trials to establish the most clinically useful cost/benefit regarding side effects and analgesic action. In addition, none of these drugs have FDA approval for CRPS. Alpha-adrenoceptor blockers including phenoxybenzamine, phentolamine, yohimbine, and clonidine have been used in CRPS with equivocal results. The use of propranolol has been abandoned. A calcium channel blocker, ziconotide, administered intrathecally has been used in CRPS. There is little compelling scientific evidence for sodium channel blocker antiepileptic agents in CRPS. Effective doses of intravenous lidocaine may be difficult to achieve due to development of adverse cardiovascular effects. Anti-TNF (e.g., infliximab), thalidomide, and lenalidomide need additional double-blind, controlled trials. Other agents are listed below:

SYSTEMIC INTRAVENOUS BISPHOSPHONATES

Alendronate, pamidronate, neridronate, etidronate, risedronate, ibandronate, and clodronate (also known as clodronate disodium, clodronic acid, or dichloromethylene bisphosphonate) are classed as bisphosphonates. These agents may be capable of relieving pain by modulation of nociceptive primary afferents in bone and pain-associated changes in the spinal cord (Schott, 1997 and 2001). Although bisphosphonates are promoted for systemic intravenous treatment of CRPS, their use in CRPS has not been approved by the FDA. One high-quality RCT (Varennna et al., 2000) found a significant improvement in pain reduction in individuals receiving intravenous clodronate, compared to placebo. Another RCT (Adami et al., 1997) found that intravenous alendronate significantly improved pain, compared to placebo.

More recent studies of the use of bisphosphonates in CRPS have been performed. Verenna et al. (2013) performed a randomized, double-blind, placebo-controlled clinical trial of IV neridronate in 82 individuals with CRPS type 1; significant improvements in the Visual Analogue Scale (VAS) versus placebo were reported. However, this drug is approved only for treatment of osteogenesis imperfecta and only in Italy. O'Connell et al. (2013) found low-quality evidence that bisphosphonates may effectively reduce pain when compared with placebo, at least in the short term. They concluded that although the efficacy of bisphosphonates was promising, it has not been proven efficacious with confidence and warrants further investigation. While the UK Guidelines found strong evidence of efficacy of IV alendronate, IV pamidronate, and IV clodronate in CRPS, none of these drugs are approved for use in either the UK or the US (Goebel et al., 2012). Trials of bisphosphonates in CRPS type 1 have demonstrated the potential to reduce pain associated with bone loss. Most studies found improvement in pain symptoms and increased functionality. However, because of small sample sizes, more studies are needed to recommend bisphosphonates for CRPS treatment (Kosharsky et al., 2013).

In a comprehensive review of CRPS, Borchers and Gershwin (2014) note that there is convincing evidence that bisphosphonates can significantly relieve spontaneous and stimulus-evoked pain and improve function in individuals with early disease. According to Wheeler (2014), IV clodronate and alendronate have been shown to significantly improve pain, swelling, and range of motion in individuals with acute CRPS. Varennna et al. (2014) reported that studies show that bisphosphonates may be effective in the early stages of CRPS. However, according to Casale et al. (2015), only a few trials are available that would allow definitive conclusions.

A study by Eun Young et al. (2016) compared the effectiveness of IV pamidronate and oral prednisolone in 21 individuals with CRPS subsequent to hemiplegic strokes. Individuals were randomly assigned to pamidronate (n=11) or prednisolone (n=10). Subjective pain and hand edema (circumference of the middle finger and the wrist were measured at baseline and at 1, 2, and 4 weeks following the end of treatment). Both groups showed significant improvement in pain scores that were maintained to the 4-week period. Finger edema reduction was maintained at 4 weeks for those in the steroid group. Wrist edema reduction was maintained for 4 weeks in those on pamidronate. The authors noted the need for larger controlled longer term studies to validate the findings. An editorial discussing the study indicated that for now pamidronate appears to be the drug of choice in both posttraumatic and poststroke CRPS type 1 (Van Daele, 2016). Additionally, according to Frediani and Bertoldi (2015), IV clodronate has been used

off-label for decades for CRPS type 1 with doses that range between 3 and 5 grams.

Therefore, for intravenous bisphosphonates in the treatment of CRPS, there is limited evidence that they improve the net health outcome.

SYSTEMIC INTRAVENOUS BUPIVACAINE

No data were found for IV bupivacaine treatment of CRPS.

SYSTEMIC INTRAVENOUS DEXMEDETOMIDINE

Clinical investigations of dexmedetomidine for the treatment of CRPS are limited. According to Kosharakyy et al. (2013), further studies are needed to assess the efficacy of dexmedetomidine for treatment of chronic pain. Dexmedetomidine has not been approved by the FDA for treatment of CRPS.

SYSTEMIC INTRAVENOUS DIMETHYLSULFOXIDE (DMSO)

A number of free radicals have been proposed for use in CRPS, including DMSO, but no convincing evidence is available. DMSO has been FDA approved only for interstitial cystitis (Casale et al., 2015).

SYSTEMIC INTRAVENOUS IMMUNOGLOBULIN G

In a double-blind placebo-controlled trial, intravenous immunoglobulin G (IVIG) was provided to a randomly assigned group of 13 individuals who had refractory CRPS for 6 to 30 months. Pain levels were greater than 4 on a 0 to 10 rating scale. With IVIG treatment, the average pain intensity was 1.55 units lower than with placebo treatment ($P=0.001$). Despite these results, the researchers acknowledge the need for studies to determine best dose, duration of effect, and frequency of treatment (Goebel et al., 2014).

In their systematic reviews, both Cossins et al. (2013) and Goebel (2012) found limited evidence for the efficacy of low-dose IVIG. An opinion article suggested that immune mechanisms may be involved in long-standing pain, and IVIG may moderate pain by reducing immune activation (Gonzales et al., 2012). However, no data were presented to support the theory.

Like ketamine, the NINDS considers IVIG to be an emerging treatment for CRPS (NINDS, 2013). The authors cited a small study (Gobel, 2010, previously reported) and note that a larger study involving individuals with acute phase CRPS is planned. IVIG has not been FDA approved for treatment of CRPS.

In a review of data, Abdi (2015) continues to classify IVIG as an experimental approach to the treatment of CRPS. Gierthmuhlen et al. (2014), noted two aspects of IVIG in the treatment of CRPS: CRPS may have an autoimmunity component, and there have been observations of pain relief with IVIG in CRPS.

Despite these points, the relevance of these findings remain unclear. Furthermore, per Gierthmuhlen et al. (2014) and Freedman et al. (2014), there is a scarcity of data; thus, further research is necessary.

In addition, IVIG has not received FDA approval for use in CRPS.

SYSTEMIC INTRAVENOUS KETAMINE

In a small observational study, ketamine was titrated from 10 mg/hr to a maximum dose of 40 mg/hr to achieve comfort without evidence of significant side effects. Infusions were provided to six individuals with CRPS over a 5-day period. Individuals were admitted to a monitored telemetry unit and maintained on their usual medication during the infusion period. Daily pain assessments and ketamine blood levels were collected. Minimal pain relief was observed on day 1, but significant pain relief ($P<0.05$) was observed by day 3, compared to baseline, and continued throughout the 5-day period. However, uniformity of relief was not achieved. On day 5, there was little or no change in the pain measure assessed as the worst pain experienced over the last 24 hours in six of the 16 individuals. In this study, there was no follow-up after the 5-day period (Goldberg et al., 2010).

Twenty individuals were infused with ketamine in anesthetic doses over 5 days. Significant pain relief was observed at 1, 3, and 6 months following treatment. Complete remission from CRPS was observed at 1 month in all individuals, at 3 months in 17 individuals, and at 6 months in 16 individuals. Although suggested benefit in relief of CRPS symptoms, the authors state that RCTs are needed to prove efficacy (Kiefer et al., 2008).

Sigtermans et al. enrolled 60 individuals in a double-blind randomized placebo-controlled trial (2009). Individuals were admitted to a short-stay inpatient facility where they received either ketamine or saline infused over 4 days. Ketamine was titrated at regular intervals to a maximum of 30 mg/hr for a 70-kg individual. The infusion rate was

increased when pain relief was insufficient. Liver function (daily) and blood pressure (TID) were measured. Pain scores over the 12-week monitoring period were significantly lower than those in individuals receiving placebo ($P<0.001$); however, the significance was lost between the groups at week 12 ($P=0.07$). Individuals receiving the drug experienced more psychomimetic side effects than controls (93% vs. 17%; $P<0.001$). In fact, individual and investigator guesses of administered treatment were correct in 74% and 88%, respectively, most likely due to psychomimetic side effects. Functional improvement did not occur in either group. The authors suggested that 4-day treatment with low-dose ketamine is safe, with psychomimetic side effects that were acceptable to most individuals.

Schwartzman et al. (2009) described a double-blind placebo-controlled outpatient trial that randomly assigned 19 individuals with refractory CRPS into a ketamine group ($n=9$) or a placebo group ($n=10$). All subjects were infused with 100 mL of normal saline with or without ketamine for 4 hours (25 mL/h) daily for 10 days (5 days on, 2 days off, 5 days on). The maximum ketamine rate was 0.35 mg/kg/h not to exceed 25 mg/h. Subjects in both arms received clonidine and versed. Individuals were seen at 2 weeks and then monthly for the following 3 months. Following treatment, the ketamine group showed a 21.4% reduction in pain scores ($P<0.01$), while the placebo group demonstrated a nonsignificant 3.1% reduction ($P>0.05$). There was no change in individual activity in either the pre- or posttreatment phase. Side effects were described as nausea, headache, tiredness, or dysphoria in four of nine individuals in the ketamine group and in two of 10 individuals in the placebo group. The authors suggest that the lack of any psychomimetic side effects may be due to the addition of midazolam and clonidine. This trial was conducted with multiday subanesthetic doses of ketamine, although the authors note (citing the study by Kiefer et al.) that in their experience, only the 5-day intravenous ketamine regimen at anesthetic doses with midazolam and clonidine provide complete remission of CRPS symptoms lasting over 5 years. In fact, this trial was prematurely terminated because during the 2-year trial period the researchers found that doses of 50 mg/h (200 mg over a 4-hour period) provided much greater pain relief lasting for a longer period of time without complications. Therefore, they did not want to continue treating individuals at the low ketamine dose.

In a commentary on the previous two studies involving ketamine, Bell and Moore (2010) questioned the safety of repeated infusions of ketamine should pain return. In fact, not only did safety questions remain, but optimal ketamine treatment regimens for chronic pain have yet to be established.

A retrospective study (without a control group) of ketamine infusions for refractory chronic pain was conducted at the University of Chicago Medical Center (Patil and Animescu, 2013). Forty-nine individuals underwent 369 infusions. Of these individuals, 18 (37%) had a diagnosis of CRPS, eight had refractory headaches and seven severe back pain. All individuals reported significant reduction in VAS scores and reportedly, up to half of the individuals experienced pain relief for up to 3 weeks.

Cossins et al. (2013) found moderate evidence for low-dose ketamine, but, according to the author, this evidence becomes compromised by the findings by Noppers et al. (2011), of liver failure after prolonged or repeated treatment. O'Connell et al. (2013) found low-quality evidence that IV ketamine may effectively reduce pain. Moreover, it is associated with many side effects, and, in the studies cited, the effect was not sustained beyond 4 to 11 weeks posttreatment.

The NINDS considers ketamine an emerging treatment for CRPS. Investigators are using low doses of ketamine to either reduce substantially, or eliminate, the chronic pain of CRPS. "In certain clinical settings, ketamine has been shown to be useful in treating pain that does not respond well to other treatments." It should be noted that the information on its website does not represent endorsement of the treatments or an official position by the NINDS.

According to Kosharsky et al. (2013) in a literature review, there are obstacles to the use of ketamine for chronic pain, including low oral bioavailability, a lack of an easily available formulation for chronic delivery, concerns over psychomimetic side effects, and mixed efficacy in clinical trials. The authors concluded that the use of ketamine infusions for the treatment of CRPS shows promise, but further prospective, randomized, double-blind placebo-controlled studies of anesthetic and subanesthetic doses of ketamine are needed.

In a systematic literature review specific to ketamine treatment for CRPS, Azari et al. (2012) concluded that the drug, while promising, needs well-designed clinical trials to determine the optimum dose, route, and timing of administration. The efficacy, safety, and long-term benefit also need to be demonstrated.

Wheeler (2014) indicates that while the rationale for ketamine for CRPS seems reasonable, no studies have shown benefit using objective outcome measures with double-blind randomized controlled methodology. In addition, several research questions remain to be settled. While Birklein et al. (2015) opines that currently the only medical treatment that is effective against chronic CRPS pain is ketamine infusions, the individual's function is not improved and the infusions have side effects.

An UpToDate review (Abdi, 2015) continues to classify ketamine as an experimental approach to treatment of CRPS. Additionally, researchers indicate that overall evidence for intravenous ketamine treatment in CRPS is limited and adverse effects restrict its usage. Further studies are necessary to assess efficacy and risk-benefit ratio (Casale et al., 2015; Gierthmuhlen et al., 2014). Ketamine has not been FDA approved for treatment of CRPS.

An additional study from Drexel University College of Medicine noted that poor responders to ketamine treatment had a lower body mass index (BMI) than responders. The researchers investigated the mechanisms underlying lower BMI that characterizes CRPS individuals who respond poorly to IV ketamine therapy. They also sought to identify potential biomarkers for predicting response. Regulation of proopiomelanocortin (POMC) expression is crucial in normal body weight homeostasis. The authors found that although ketamine treatment did not alter POMC expression, poor responders had higher levels of POMC mRNA than responders. There was a positive correlation between the pretreatment levels of miR-34a to BMI and response to therapy. Larger studies are required to confirm the findings (Shenoda et al., 2016).

The above authors also investigated treatment-induced circulating microRNA as potential biomarkers. According to the authors, differences in miRNA signature in responders and poor responders before and after therapy indicate the prognostic value of miRNA response to intravenous ketamine (Douglas et al., 2015).

An observational longitudinal cohort study was conducted to assess the efficacy of subanesthetic ketamine infusions on children with chronic pain. Sixty-three individuals who received infusions were included. Of these, 23 had CRPS (37%). Ketamine infusions at doses between 0.1 and 0.3 mg/kg/h lasted for 4 to 8 hours per day up to a maximum of 16 hours over a maximum of 3 consecutive days. Pain scores after each infusion were significantly reduced from pretreatment scores ($P < 0.001$). Greater reductions occurred in individuals with CRPS than in those with other chronic pain syndromes. Ketamine infusions did not change oral morphine intake compared to baseline doses. No follow-up except after treatment days was reported. Effect on function was not reported. The authors note the need for further studies to assess the optimum dose and long-term effect of ketamine on CRPS in children and adolescents (Sheehy et al., 2015).

A study to assess the effects of long-term ketamine treatment on cognitive function was reported by Kim et al. in 2016. Thirty individuals with CRPS were divided into a long-term frequent ketamine treatment group ($n=14$) and a non-long-term group ($n=16$). The participants completed questionnaires including demographic and clinical characteristics and variables affecting cognitive function. They also performed neuropsychological tests. Individuals who received long-term ketamine treatment showed impairment in cognitive function—specifically in executive function—compared with the non-long-term individuals.

Ketamine in anesthetic dosage was administered to five individuals with CRPS of a mean of 8 years' duration. The drug was administered over a 10-day period and individuals received between one and five doses. Pain reduction began on the 4th or 5th day of treatment. No improvement was noted in function. Pain reduction lasted from 1.5 to 2.5 months following treatment, then relapsed to baseline level. The authors observed the short-term analgesic effect of the therapy but also noted the lack of effect on movement or function of the affected limbs (Puchalski and Zyluk, 2016).

Wheeler (2015) observed that the optimal dosing and duration of infusions of ketamine is unknown. These and other questions have yet to be answered. In addition, studies to date have not validated the benefit of ketamine using objective outcome parameters with double-blind randomized controlled methodology.

SYSTEMIC INTRAVENOUS LIDOCAINE

A study of lidocaine in CRPS, used as a continuous intravenous infusion in escalating doses, was reported. The treatments were administered to 49 individuals with CRPS over 5 days. Pain parameters were assessed at 1, 3, and 6 months following therapy. The researchers reported significant reduction in pain that lasted an average of 3 months (Schwartzman et al., 2009).

When intravenous lidocaine was compared with lidocaine used in a lumbar sympathetic block, IV lidocaine failed to produce significant changes in spontaneous and evoked pain intensity measurement compared to pretreatment values (Meier et al., 2009).

There are some uncontrolled studies of lidocaine in neuropathic pain, but few address IV lidocaine in CRPS (Mackey and Feinberg, 2007; Carroll et al., 2010; Challapalli et al., 2005). One recent small study found benefit from lidocaine infusions for CRPS (Schwartzmann et al., 2009), while another found no significant changes in pain resulting from IV lidocaine use (Meier et al., 2009). Additionally, there is no consensus for this treatment, and long-term response is unknown.

According to Harden et al. (2013), lidocaine infusions have fallen out of favor and are lacking evidence of efficacy. Kosharsky et al. (2013) performed a comprehensive review and noted that the best results were reported in Schwartzman et al. (2009), but this study was small and nonrandomized. They therefore concluded that additional studies were needed to confirm the results. O'Connell et al. (2013) and Gierthmuhlen et al. (2014) found low-quality evidence (based on one study) that high-dose IV lidocaine may have a small effect on pain when compared with diphenhydramine. Casale et al. (2015) noted that systemic lidocaine is only therapeutic in cases of cold-induced allodynia. However, its channel-blocking activity is unspecific and effective doses may be difficult to achieve due to adverse cardiovascular effects.

Lidocaine is not FDA approved for intravenous infusion for treatment of CRPS.

SYSTEMIC INTRAVENOUS MAGNESIUM

In a pilot study, intravenous magnesium was provided to eight individuals, while two individuals received normal saline as placebo. The placebo results were not analyzed or reported. At follow-up of 12 weeks, pain was significantly reduced from baseline. Impairment level and quality of life also improved, while there was no difference in skin sensitivity or functional limitations (Collins et al., 2009). This is a small study; the results need to be confirmed in a large, well-designed trial. In a 2015 review, Casale et al. indicated that intravenous magnesium can be considered a potential nonpharmacological supplement because it has fewer side effects than other treatments; however, further studies are necessary to identify the best route of administration. No additional studies of magnesium for treatment of CRPS have been performed. The drug is not FDA approved for CRPS.

SYSTEMIC INTRAVENOUS MANNITOL

It has been proposed that free radical scavengers may have a role in curtailing the CRPS disease process. Perez et al. conducted a randomized, placebo-controlled, double-blind trial involving 41 individuals that compared intravenous mannitol in normal saline, infused in 4 hours over 5 days, with equal volumes of normal saline as placebo. Both groups received physical therapy. Pain was monitored using the VAS during the trial. Impairment and disability levels and quality of life were assessed up to 9 weeks. At the end of the study, no significant differences were found between mannitol and placebo treatment (Perez et al., 2008).

A small study compared treatment strategies in four groups of individuals with CRPS type 1 (Lee et al., 2012). Group A was administered an NSAID (n=10), group B oral gabapentin (n=12), group C IV mannitol 10% and a steroid (n=11), and group D IV mannitol, steroid, and oral gabapentin (n=26). The best results occurred in group D which showed recovery of grip strength and improvement in pain level and finger range of motion. This is a small study that needs replication. Moderate evidence of nonefficacy was found in the UK review (Goebel et al. 2012). O'Connell et al. (2013) found very low-quality evidence that IV mannitol is not effective.

Intravenous mannitol has not been FDA approved for treatment of CRPS.

SYSTEMIC INTRAVENOUS OPIOIDS

According to Freedman et al. (2014), opioids for chronic benign pain syndromes remain controversial secondary to potential for abuse, diversion, and overdoses leading to death. Recent reviews found in Casale et al. (2015) reported that opioids are not recommended as systemic treatment for CRPS. Although it is generally recognized that opioids have little or no effect on chronic nerve pain, there have been some reports of pain reduction and improved quality of life in individuals with chronic nerve pain. However, no controlled studies have been performed to demonstrate this finding.

INTRATHECAL AGENTS

INTRATHECAL BACLOFEN

A search of the literature for studies of intrathecal baclofen (ITB) in CRPS revealed one small randomized crossover trial (van Hilten et al., 2000; seven individuals) suggesting that either continuous therapy or bolus injections of the agent might be effective in the treatment of dystonia in RSD. Therefore, there is limited evidence suggesting that ITB in CRPS improves the net health outcome. However, ITB has not been approved by the FDA for use in CRPS.

ITB was evaluated for treatment of dystonia in CRPS. Thirty-eight individuals met the responder criteria, and 36 of those received a pump for continuous ITB administration in a dose-escalation study. Dose effect of baclofen on dystonia severity was shown in 31 individuals with doses up to 450 mcg/day. One individual did not respond, and three individuals dropped out. Thirty-six individuals entered an open-label study. Intention-to-treat analysis at 12 months found improvement in dystonia, pain, disability, and quality of life. Eighty-nine adverse events occurred in 26 individuals. Of these, 19 were directly related to baclofen, 52 to pump defects, and 18 to unspecified problems. The pump was explanted in 6 individuals during the follow-up phase. Although CRPS symptoms improved and ITB remained efficacious over a period of 1 year, the authors noted the problems with high complication rate and

suggested that methods to improve individual selection and pump integrity are warranted (Van Rijn et al., 2009).

A study to assess the effect of varying the infusion rate on the efficacy and safety of ITB delivery was reported (van der Plas et al., 2011). Individuals with CRPS-related dystonia who had no beneficial response to a minimum dose of baclofen, or who were intolerant of dose escalation because of side effects, were randomly assigned to slower infusion rate delivery (SIRD) or four times faster infusion rate delivery (FIRD). There were no significant differences between the FIRD and the SIRD groups for the primary outcomes of dystonia and pain. The same researchers in a later open study found significant improvement in global intense pain, sharp pain, dull pain, and deep pain during the first 6 months in a study of individuals with CRPS-related dystonia receiving titrated doses of ITB. After this period, pain scores leveled off despite further improvement of dystonia and continued ITB titration (van der Plas et al., 2013).

ITB is advised for individuals who display a dystonic component to CRPS. Harden et al. (2013) reports level 3 evidence for ITB in dystonic CRPS. According to these authors, if oral baclofen is effective but poorly tolerated, administration by intrathecal pump is a treatment option. Although O'Connell et al. (2013) concluded that ITB infusion needs further study, Goebel et al. (2012) recommended using ITB if other options have failed.

INTRATHECAL CLONIDINE

Like epidural clonidine, intrathecal clonidine infusion requires additional investigation (Tran et al., 2010). A small study showed a 30% or greater reduction in pain 2 hours after injection in 10 of 22 individuals. However, the change in pain report did not correlate with the percentage change in areas of hyperalgesia ($P=0.09$) or allodynia ($P=0.24$). The authors note that analgesia does not parallel antihyperalgesia with these treatments (Rauck et al., 2015). No other recent studies were found.

INTRATHECAL GLYCINE

Intrathecal glycine was investigated as a potential therapy for pain and movement disorders in a randomized double-blind placebo-controlled trial in 19 individuals. Over a 4-week period, no significant differences were found between the treatment and control groups (Munts et al., 2009).

INTRATHECAL METHYLPREDNISONE

A double-blind, randomized placebo-controlled parallel-group trial was reported using a single intrathecal administration of methylprednisolone. The trial was stopped prematurely at 6 weeks when no difference was found between the treatment and control group (Munts et al. 2010; Gierthmuhlen et al., 2014). A 2014 review article (Rijsdijk et al., 2014) comments that the reports of the efficacy of intrathecal methylprednisolone are contradictory and that its safety is debated.

INTRATHECAL OPIOIDS

Individuals with intractable malignant and nonmalignant pain were treated with intrathecal opioid infusion with an implantable pump. At follow-up of 3 years, reduction of nonmalignant pain on the VAS was reduced by more than 50% in 71.3% of individuals. According to the authors, the treatment should be provided only in specialized centers (Koulousakis et al., 2007). According to Singh et al. (2026), a morphine pump should be carefully considered for chronic pain of nonmalignant origin. Other studies recommend intrathecal opioid administration as an option for nonmalignant pain, including CRPS, which can significantly improve quality of life in selected individuals (Koulousakis et al., 2007). A Consensus Guideline (Deer et al., 2010) published an algorithm for intrathecal therapies which advised opioids and/or ziconotide be first-line treatments for CRPS. According to the NINDS, intrathecal infusion requires lower doses than what is required for oral administration, therefore decreasing side effects and increasing effectiveness.

INTRATHECAL OPIOIDS IN COMBINATION WITH BUPIVACAINE

In small retrospective studies, bupivacaine was found to be stable in an implantable infusion system (Hildebrand et al., 2001; Goucke et al., 2010). However, clinical outcomes were mixed. In retrospective studies to assess the efficacy of bupivacaine when added to IT opioids for treatment of nonmalignant pain, a significant improvement in pain reduction, disability, and quality of life scores was reported (Kumar et al., 2009). In a larger retrospective study ($n=126$), a significant reduction in opioid dose escalation was demonstrated when bupivacaine combined with opioids was compared with opioids alone (Veizi et al., 2011). It should be noted that of the 143 subjects enrolled in these trials, only 12 were treated for CRPS. The only randomized trial of opioids alone or opioids with bupivacaine found that the addition of bupivacaine to IT opioids failed to produce improvement in pain control, and the researchers concluded that IT mixtures of opioids and bupivacaine are not efficacious in the treatment of chronic nonmalignant pain. There is a need for additional large randomized trials to define the use of IT bupivacaine, including long-term toxicity and neuropathology, particularly when used with other agents. Also unknown is the type of pain for which IT bupivacaine is most efficacious (Deer et al., 2002; Kumar et al., 2009; Veizi et al., 2011; Mironer et al., 2002). Bupivacaine is not approved by the FDA for IT administration.

INTRATHECAL OPIOIDS IN COMBINATION WITH LIDOCAINE

There is a lack of scientific evidence of positive impact on health outcomes with IT lidocaine/opioid treatment in CRPS. Lidocaine is not FDA approved for IT infusion.

INTRATHECAL ZICONOTIDE (PRIALT®)

A randomized, placebo-controlled trial with gradually increasing dosage over a 3-week period showed a statistically significant improvement in the Visual Analogue Scale of Pain Intensity (VASPI) with ziconotide (Prialt®) versus placebo. In addition, an open-label, multicenter study enrolled 644 individuals with chronic pain in an evaluation of ziconotide (Prialt®) long-term use. Of individuals with VASPI scores of 50 mm or greater at baseline who completed 1 month of therapy, 32.7% had greater than 30% improvement in VASPI scores. Also recorded was the pain impact on daily life, which significantly differed between baseline and month 2.

INTRAMUSCULAR AGENTS

INTRAMUSCULAR BOTULINUM

A search of the literature for RCTs related to intramuscular botulinum in CRPS produced one record: a small observational study of 11 individuals with CRPS type 1 affecting one upper extremity. The study suggests that botulinum A toxin may provide analgesic effects for several neuropathic pain states, including CRPS type 1, spinal cord injury pain, postherpetic neuralgia, and pain associated with brachial plexopathies (Argoff, 2002). A retrospective study of intramuscular botulinum toxin in 37 CRPS individuals with spasm/dystonia in the neck and/or upper limb girdle muscles was reported (Kharkar et al., 2011). Ninety-seven percent of individuals had significant pain relief with mean pain score decreases of 43%. These results were reported only in the short-term, up to 4 weeks. As noted by the authors, this is a study that lacks a control group, so the placebo effect cannot be discounted. Also, according to the UK Guidelines, evidence for regional botulinum toxin for CRPS-related dystonia is poor (Goebel et al., 2012). A comprehensive review (O'Connell et al., 2013), reported very low-quality evidence that sympathetic block using botulinum toxin A with a local anesthetic may effectively increase the duration of analgesia compared to local anesthetic alone by approximately 2 months. However, the authors were unclear regarding the level of pain relief that might be achieved by this intervention. Brown et al. (2014) conducted a review to summarize the highest quality literature pertaining to application of botulinum toxin in neuropathic pain conditions, including CRPS. They found level U (insufficient) evidence in CRPS.

Therefore, for intramuscular botulinum toxin A in CRPS, there is limited evidence that it improves the net health outcome. Intramuscular botulinum has not been approved by the FDA for use in CRPS.

INTRAMUSCULAR KETAMINE

In a review of topical and peripheral ketamine, Sawynok (2014) notes that peripheral administration of ketamine by localized injection produced some alterations in sensory thresholds in experimental trials in CRPS subjects, but many variables remained unchanged. Intramuscular ketamine is not FDA approved for CRPS treatment. The lack of scientific evidence does not permit conclusions regarding net health outcomes.

INTRAMUSCULAR MAGNESIUM SULFATE

A double-blind, randomized, placebo-controlled crossover study was performed to assess the effect and safety of intramuscular magnesium sulphate (IMMG) versus placebo in CRPS individuals with dystonia (Van der Plas et al., 2013). Thirty individuals were administered IMMG or placebo over 3 weeks. The primary outcome was the difference in change in the Burke-Fahn-Marsden dystonia scores between both interventions. Only 22 individuals were available for analysis, which revealed no differences between IMMG and placebo. According to the investigators, there is insufficient support for new studies evaluating the efficacy of other routes of MG administration in CRPS-related dystonia. IMMG has not been approved by the FDA for use in CRPS.

EPIDURAL AGENTS

EPIDURAL CLONIDINE

Epidural infusion with an alpha 2-adrenergic agonist such as clonidine has been proposed for the relief of purportedly "sympathetically maintained pain," such as RSD (Rauck et al., 1993). This method of treatment was classified as a sympathetic blockade in the review by Forouzanfar et al. (2002). A single high-quality RCT (Rauck et al., 1993) in 27 individuals found that epidural clonidine in individuals diagnosed with RSD reduced pain significantly more than placebo. According to Harden et al. (2013), the effectiveness of epidural analgesia for treatment of CRPS has been demonstrated in several studies. The value of the treatment is to allow a more rigorous PT program. van Elijs suggests that epidural infusions "can be tried" for individuals refractory to other conventional treatment (van Elijs 2011). The main limitation to continuous infusions is the high infection rate of indwelling lines which, according to Harden et al., needs to be defined by further prospective study on infusion techniques in CRPS individuals. O'Connell et al. (2013) found very low quality evidence that clonidine provides relief of pain that is refractory to

sympathetic blockade (one study), and recommends further study. According to Freedman et al. (2014), there is no convincing evidence for epidural clonidine to treat sympathetic pain in CRPS. Therefore, for epidural clonidine in CRPS, there is limited evidence that it improves the net health outcome. However, epidural clonidine has not been approved by the FDA for use in CRPS.

INTRATHORACIC MEDICATIONS

Intrathoracic (i.e., intrapleural or intrapulmonary) administration of nonopioid medication for CRPS that does not have as its goal direct chemical ablation of sympathetic ganglia or fibers does not appear to be used.

In summary, despite optimism for the use of various parenterally administered nonopioid drugs for CRPS, there are no completed clinical trials on the efficacy of these treatments with consistently applied evidence-based medicine criteria. Most reports of trials in CRPS represent small anecdotal clinical studies with few experimental findings. Unquestionably, a consensus definition of CRPS, with standardized diagnostic criteria, is needed. Practical agreement about the minimal clinical criteria (signs and symptoms) that define CRPS does exist among neurologists, anesthesiologists, and others. Without a universally accepted definition and diagnostic criteria for CRPS, it is difficult to accurately identify CRPS individuals, to select individuals for clinical trials, to validate experimental human and animal model systems for research, and to formulate testable hypotheses (NINDS, 2001). Finally, none of the nonopioid agents proposed for the treatment of CRPS, and in particular none of the parenterally administered agents, have been approved by the FDA.

PLASMAPHERESIS

Plasmapheresis is a method of withdrawing blood and separating it into plasma and cells, and transfusing the cells back into the bloodstream. It is used to remove antibodies when treating autoimmune conditions. Although it is hypothesized that there is an autoimmune component to CRPS, no outcome data were found specific to CRPS treatment with plasmapheresis. The lack of scientific evidence does not permit conclusions regarding net health outcomes.

PLASMA EXCHANGE

Plasma exchange is an extracorporeal therapy that extracts the individual's whole blood and separates it into plasma and blood cells. The plasma is removed and replaced with another solution such as human albumin in saline or a specifically prepared donor plasma. The reconstituted plasma substitute along with the blood cells is then returned to the individual.

A study from Drexel University College of Medicine described a retrospective case series of individuals with CRPS and a clinical presentation suggestive of a small fiber neuropathy (SFN) who were treated with plasma exchange. The use of plasma exchange was based on a hypothesis proposing an autoimmune etiology for CRPS. Thirty-three individuals who had not responded, or responded poorly, to their current treatment received a series of plasma exchanges (mean, 7.2 treatments) over a 2- to 3-week period. Three individuals showed no improvement in pain with the treatment, and one individual reported short-term relief that returned to pretreatment level within 3 days. The remaining individuals reported significant pain reduction that was either maintained with immune-modulating therapies of weekly plasma exchange (n=15), or oral immune-modulating therapy (n=8) or they slowly returned to pretreatment pain levels with no further therapy (n=6). The authors conceded that the study, because of its retrospective, nonrandomized, and uncontrolled nature, is limited. Moreover, because the individuals described were only those with SFN, the results cannot be extrapolated to the entire CRPS population. They concluded that randomized, placebo-controlled studies may be required to confirm the results (Aradillas et al., 2015.)

References

Abdi S. Complex regional pain syndrome in adults: Treatment, prognosis, and prevention. 01/19/2023. UpToDate website. Available at: <http://www.uptodate.com/contents/prevention-and-management-of-complex-regional-pain-syndrome-in-adults?source=machineLearning&search=complex+regional+pain+syndrome&selectedTitle=2~60§ionRank=1&anchor=H6#H6>. Accessed May 21, 2026.

Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. *Ann Rheum Dis*. 1997;56:201-214.

- Albazaz R, Wong YT, Homer-Vanniasinkam S. Complex regional pain syndrome: A review. *Ann Vasc Surg*. 2008;22:297-306.
- Ali Z, Raja SN, Wesselmann U, et al. Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain. *Pain*. 2000;88:161-168.
- Aquirre J, Del Moral A, Cobo I, et al. The role of continuous peripheral nerve blocks. *Anesthesiol Res Pract*. 2012;2012:560879.
- Aradillas E, Schwartzman RJ, Grothusen JR, et al. Plasma exchange therapy in patients with complex regional pain syndrome. *Pain Physician*. 2015;18:383-394.
- Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. *Clin J Pain*. 2002;18(6)Suppl:S177-S181.
- Atkins RM. Complex regional pain syndrome: aspects of current management. *J Bone Joint Surg [Br]*. 2003;85-B(8):1100-1106.
- Azari P, Lindsay DR, Briones D, et al. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. *CNS Drugs*. 2012;26:215-228.
- Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. *JAMA*. 1998;280:1831-1836.
- Bailey J, Nelson S, Lewis J, et al. Imaging and clinical evidence of sensorimotor problems in CRPS: Utilizing novel treatment approaches. *J Neuroimmune Pharmacol*. 2013;8:564-575.
- Bean DJ, Johnson MH, Kydd RR. The outcome of complex regional pain syndrome type 1: a systematic review. *J Pain*. 2014;15:677-690.
- Bell RF, Moore RA. Intravenous ketamine for CRPS: Making too much of too little? *Pain*. 2010;150(1):10-11.
- Bennett GJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. *J Pain Sympt Manag*. 2000;19(1 suppl):S2-6.
- Birklein F, O'Neill D, Schlereth T. Complex regional pain syndrome: An optimistic perspective. *Neurology*. 2015;84:89-96.
- Blanchard J, Ramamurthy S, Walsh N, et al. Intravenous regional sympathectomy: A double-blind comparison of guanethidine, reserpine, and normal saline. *J Pain Symptom Manage*. 1990;5:357-361.
- Bonelli S, Conoscente F, Movilia PG, et al. Regional intravenous guanethidine vs. stellate ganglion block in reflex sympathetic dystrophies: a randomized trial. *Pain*. 1983;16:297-307.
- Bonica JJ. Causalgia and other reflex sympathetic dystrophies. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG (eds). *Proceedings of The 2nd World Congress on Pain. Advances in Pain Research Therapy*. Vol. 3. New York: Raven Press 1979:141-166.
- Borchers AT, Gershwin ME. Complex regional pain syndrome: A comprehensive and critical review. *Autoimmun Rev*. 2014;13:242-265.
- Bounameaux HM, Hellemans H, Verhaeghe R. Ketanserin in chronic sympathetic dystrophy. An acute controlled trial. *Clin Rheumatol*. 1984;3:556-557.
- Brown DL. Somatic or sympathetic block for reflex sympathetic dystrophy. Which is indicated? *Hand Clin*. 1997;13(3):485-497.
- Bruehl S. Complex regional pain syndrome. *BMJ*. 2015;351:h2730.
- Bruehl S. Do psychological factors play a role in the onset and maintenance of CRPS-1? In: Harden RN, Baron R, WJ, (eds). *Complex Regional Pain Syndrome*. Seattle: IASP Press 2001;22.

Breuer AJ, Mainka T, Hansel N, et al. Short-term treatment with parecoxib for complex regional pain syndrome: A randomized, placebo-controlled double-blind trial. *Pain Physician*. 2014;17:127-37.

Breuer B, Pappagallo M, Ongseng F, et al. An open-label pilot trial of ibandronate for complex regional pain syndrome. *Clin J Pain*. 2008:685-689.

Brown EA, Schulz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. *Pain Manag*. 2014;4:129-151.

Brunner F, Schmid A, Kissling R, et al. Bisphosphonates for the therapy of complex regional pain syndrome I – systematic review. *Eur J Pain*. 2009;13:17-21. Epub 2008 Apr 28.

Buskard NA. Plasma exchange and plasmapheresis. *Can Med Assoc J*. 1978;119(7):681-683. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1818776/>. Accessed May 21, 2026.

Butler SH. Disuse and CRPS. In: Harden RN, Baron R, Janig W, eds. *Complex Regional Pain Syndrome*. Vol. 22. Seattle: IASP Press; 2001:141-150.

Borchers AT, Gershwin ME. Complex regional pain syndrome: a comprehensive and critical review. *Autoimmun Rev*. 2014;13:242-265.

Campbell J, Raga S, Meyer R. Painful sequelae of nerve injury. In: Dubner R, Gebhart G, Bond M, (eds). *Procs 5th World Congress on Pain*. Amsterdam: Elsevier Science Publishers; 1988:135-143.

Campbell J, Raga S, Meyer R. Painful sequelae of nerve injury. In: Dubner R. Central sprouting of myelinated afferents. *Nature*. 1992;355:75-78.

Candan B, Gungor S. Comparative Analysis of Temperature Variations Following Sympathetic Blocks in Warm and Cold Subtypes of Complex Regional Pain Syndrome (CRPS): A Retrospective Cohort Study. *J Clin Med*. 2025 Mar 18;14(6):2060.

Carroll I, Clark JD, Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. *Ann Neurol*. 2009;65:348-51.

Carroll I, Curtin CM. Management of chronic pain following nerve injuries/CRPS type II. *Hand Clin*. 2013;29:401-408.

Carroll IR, Younger JW, Mackey SC. Pain quality predicts lidocaine analgesia among patients with suspected neuropathic pain. *Pain Med*. 2010;11:417-421.

Casale R, Atzeni F, Sarzi-Puttini P. The therapeutic approach to complex regional pain syndrome: light and shade. *Clin Exp Rheumatol*. 2015;331 Suppl 88:S126-139.

Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) for Infusion Pumps (280.14). Effective: 12/17/2004. Available at: https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=223&ncdver=2&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=Pennsylvania&Keyword=infusion+pumps&KeywordLookUp=Title&KeywordSearchType=And&from2=index_chapter_list.asp&list_type=&bc=qAAAABAAAA&. Accessed May 26, 2026

Centre for Reviews and Dissemination (CRD). Abstract and Commentary for: Forouzanfar T, Koke AJA, van Kleef M, Weber WEJ. Treatment of complex regional pain syndrome type I. National Health Service, University of York: York, U.K. 3:2003b.

Centre for Reviews and Dissemination (CRD). Abstract and Commentary for: Jadad AR, Carroll D, Glynn DJ, McQuay HJ. Intravenous regional sympathetic blockade for pain relief in reflex sympathetic dystrophy: a systematic review and a randomized, double-blind crossover study. National Health Service, University of York: York, U.K. 3:2003b.

Cepeda MS, Carr DB, Lau J. Local anesthetic sympathetic blockade for complex regional pain syndrome. *Cochrane Database Syst Rev*. 2005;19:CD004598.

Challapalli V, Tremont-Lukats IW, McNicol ED, et al. *Cochrane Database Syst Rev*. 2005;19:CD003345.

Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. *Cochrane Database Syst Rev*. 2005;4: Art. No.: CD003345.

Chaparro LE, Smith SA, Moore RA, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. *Cochrane Database Syst Rev*. 2013;24:CD008307.

Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. *Acta Chir Scand*. 1982;148:653-655.

Clinical Trials.gov. Studies for complex regional pain syndrome. Available at: [http://clinicaltrials.gov/ct2/results?cond="Complex+Regional+Pain+Syndromes"](http://clinicaltrials.gov/ct2/results?cond=). Accessed May 26, 2026.

Collins S, Zuurmond WW, de Lange JJ, et al. Intravenous magnesium for complex regional pain syndrome type 1 (CRPS 1) patients: a pilot study. *Pain Med*. 2009;10:930-940.

Colorado Division of Workers' Compensation. Complex regional pain syndrome/reflex sympathetic dystrophy: medical treatment guidelines. Denver, CO: Colorado Division of Workers' Compensation; December 27, 2011.

Correll GE, Muir JJ, Harbut RE. Use of ketamine infusion in patients with complex regional pain syndrome. *J Pain*. 2002;3(2)(suppl):17.

Cossins L, Okell RW, Cameron H, et al. Treatment of complex regional pain syndrome in adults: A systematic review of randomized controlled trials published from June 2000 to February 2012. *Eur J Pain*. 2013;17:158-173.

Costigan M, Woolf CJ. Pain molecular mechanisms. *J Pain*. 2000; 1(suppl3):35-44.

Deer TR, Serafini M, Buchser R, et al. Intrathecal bupivacaine for chronic pain: A review of current knowledge. *Neuromodulation*. 2002;5:196-207.

Deer TR, Smith HS, Cousins M, et al. Consensus Guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. *Pain Physician*. 2010;13:E175-213.

Devor M, Raber P. Heritability of symptoms in an experimental model of neuropathic pain. *Pain*. 1990;42-1:51-67.

Dielissen PW, Claassen AT, Veldman PH, Goris RJ. Amputation for reflex disease. *J Hand Surg [Br]*. 1999;24:199-202.

Douglas SR, Shenoda BB, Qureshi RA, et al. Analgesic response to intravenous ketamine is linked to a circulating microRNA signature in female patients with complex regional pain syndrome. *J Pain*. 2015;16:814-24.

Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Arch Neurol*. 2003;60:1524-1534.

Dworkin RH, O'Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. *Pain* 2013;154:2249-61.

Eckmann, MS, Ramamurthy S, Griffin JG. Intravenous regional ketorolac and lidocaine in the treatment of complex regional pain syndrome of the lower extremity: a randomized, double-blinded, crossover study. *Clin J Pain*. 2011;27:203-206.

Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of *N*-methyl-*D*-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of postherpetic neuralgia. *Pain*. 1995;61:221-228.

Eun Young H, Hyeyun K, Sang Hee I. Pamidronate effect compared with a steroid on complex regional pain syndrome type I: pilot randomized trial. *Neth J Med*. 2016;74:30-35.

Falco FJE, Patel V, Hayek SM, et al. Intrathecal infusion systems for long-term management of chronic non-cancer pain: An update of assessment of evidence. *Pain Physician*. 2013;16SE185-16.

Farcot JM, Gautherie M, Foucher G. Regional intravenous sympathetic nerve blocks. *Hand Clin*. 1997;13(3):499-517.

Fischer SG, Collins S, Boogaard S, et al. Intravenous magnesium for chronic complex regional pain syndrome type 1 (CRPS-1). *Pain Med*. 2013;14:1388-1399.

- Forouzanfar T, Koke AJ, van Kleef M, Weber WE. Treatment of complex regional pain syndrome type I. *Eur J Pain*. 2002;6(2):105-122.
- Francini F, Zoppi M, Maresca M, Procacci P. Skin potential and EMG changes induced by electrical stimulation. 1. Normal man in arousing and non-arousing environment. *Appl Neurophysiol*. 1979;42:113-124.
- Frediani B, Bertoldi I. Clodronate: new direction of use. *Clin Cases Miner Bone Metab*. 2015;12:97-108.
- Freedman M, Greis AC, Marino L, et al. Complex regional pain syndrome: diagnosis and treatment. *Phys Med Rehabil Clin N Am*. 2014; 25:291-303.
- Gatti D, Rossini M, Adami S. Management of patients with complex regional pain syndrome type I. *Osteoporos Int*. 2016; Feb 29. [Epub ahead of print].
- Geertzen JH, de Bruijn H, de Bruijn-Kofman AT, Arendzen JH. Reflex sympathetic dystrophy: early treatment and psychological aspects. *Arch Phys Med Rehabil*. 1994;75:442-446.
- Gierthmuhlen J, Binder A, Baron R. Mechanism-based treatment in complex regional pain disorders. *Nat Rev Neurol*. 2014;10:518-528.
- Gobel A, Shenker N, Padfield N, et al. Low-dose intravenous immunoglobulin treatment for complex regional pain syndrome (LIPS): study protocol for a randomized controlled trial. *Trials*. 2014;15:404-419.
- Goebel A, Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. *Autoimmun Rev*. 2013;12:682-686.
- Goebel A, Baranowski A, Maurer K, et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. *Ann Intern Med*. 2010;152:152-158.
- Goebel A, Barker CH, Turner-Stokes L, et al. Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care. London: RCP, 07/2023. Available at: https://www.rcp.ac.uk/media/4uijppdz/complex-regional-pain-syndrome-in-adults-second-edition_0.pdf. Accessed May 26, 2026.
- Goebel A, Bisla J, Carganillo R, et al. A randomised placebo-controlled Phase III multicentre trial: low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome (LIPS trial). Southampton (UK): NIHR Journals Library; 2017 Nov. (Efficacy and Mechanism Evaluation, No. 4.5.) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK464478/>.
- Goebel A, Bisla J, Carganillo R, et al. Low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome: a randomized trial. *Ann Intern Med*. 2017;167(7):476-483.
- Goebel A, DuToit N, Perez J, Huygen F. Anesthesiologists' Views on Using Immune Modulating Drugs in Pain Medicine. *Pain Practice*. 2011;11:344-352.
- Goldberg ME, Torjman MC, Schwartzman RJ, et al. Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. *Pain Physician*. 2010;13:379-387.
- Gonzales M, Fratianni C, Mamillapali C, et al. Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome. *Med Clin North Am*. 2012;96:635-654.
- Goris RJ, Dongen LM, Winters HA. Are toxic oxygen radicals involved in the pathogenesis of reflex sympathetic dystrophy? *Free Radic Res Commun*. 1987;3:13-18.
- Goris RJ. Conditions associated with impaired oxygen extraction. In: Gutierrez G, Vincent JL, eds. Tissue oxygen utilisation. Berlin: Springer Verlag; 1991:350-369.
- Goucke CR, Dusci LJ, Leeuwen SV, et al. Stability and tolerability of high concentrations of intrathecal bupivacaine and opioid mixtures in chronic noncancer pain: an open-label pilot study. *Pain Med*. 2010;11:1612-16188. Epub 2010 Oct 1.

Gschwind C, Fricker R, Lacher G, Jung M. Does perioperative guanethidine prevent reflex sympathetic dystrophy? *J Hand Surg.* 1995;20:773-775.

Gupta R, Strand N. Sympathetic Blocks: Lumbar Sympathetic Block. In: Banik RK (eds). *Anesthesiology In-Training Exam Review*. Springer, Cham. pp. 285-288.

Gupta G. Complex regional pain syndromes. 07/15/16. [Medscape Website.] Available at: <http://emedicine.medscape.com/article/1145318-treatment>. Accessed May 26, 2026.

Gutierrez G, Vincent JL, eds. Tissue oxygen utilisation. Berlin: Springer hand: an excessive inflammatory response? *Pain.* 1993;55:151-157.

Hanna MH, Peat SJ. Ketanserin in reflex sympathetic dystrophy. A double-blind placebo controlled cross-over trial. *Pain.* 1989;38:145-150.

Hannington-Kief JG. Intravenous regional sympathetic block with guanethidine. *Lancet.* 1974;i:1019-1020.

Harden RN. Complex regional pain syndrome. *Br J Anaesth.* 2001;87:99-106.

Harden RN. Gabapentin: a new tool in the treatment of neuropathic pain. *Acta Neurol Scand.* 1999;173:43-47.

Harden RN, Oaklander AL, Burton AW, et al. Reflex Sympathetic Dystrophy Syndrome. Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. *Pain Med.* 2013;14(2):180-229.

Hildebrand KR, Elsberry DD, Deer TR. Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. *Clin J Pain.* 2001;17:239-244.

Hord AH, Rooks MD, Stephens BO, et al. Intravenous regional bretylium and lidocaine for treatment of reflex sympathetic dystrophy: a randomized, double-blind study. *Anesth Analg.* 1992;74:818-821.

Hsu ES. Practical management of complex regional pain syndrome. *Am J Ther.* 2009;16:147-154.

Ilfeld BM. Continuous peripheral nerve blocks: A review of the published literature. *Anesth Analg.* 2011;113:904-925.

Jadad AR, Carroll D, Glynn CJ, McQuay HJ. Intravenous regional sympathetic blockade for pain relief in reflex sympathetic dystrophy: a systematic review and a randomized, double-blind crossover study. *J Pain Symptom Manage.* 1995;10(1):13-20.

Janig W, Koltzenburg M. What is the interaction between the sympathetic terminal and the primary afferent? In: Basbaum AI BJ-M, ed. *Towards a New Pharmacology of Pain*. Chichester: John Wiley and Sons; 1991:331-352.

Janig W. CRPS 1 and CRPS 2: a strategic view. In: Harden RN, Baron R, Janig W, eds. *Complex Regional Pain Syndrome*. Seattle: IASP Press; 2001:3-15.

Kastler A, Aubry S, Sailley N, et al. CT-guided stellate ganglion blockade vs. radiofrequency neurolysis in the management of refractory type I complex regional pain syndrome of the upper limb. *Eur Radiol.* 2013;23:1316-1322.

Kettler RE, Abram SE. Intravenous regional droperidol in the management of reflex sympathetic dystrophy: a double-blind, placebo-controlled, crossover study. *Anesthesiology.* 1988;69:933-936.

Kharkar S, Ambady P, Venkatesh Y, et al. Intramuscular botulinum toxin in complex regional pain syndrome: case series and literature review. *Pain Physician.* 2011;14:419-424.

Kho HK. The impact of acupuncture on pain in patients with reflex sympathetic dystrophy. *Pain Clin.* 1995;8:59-61.

Kiefer RT, Rohr P, Unertl K, et al. Recovery from Intractable Complex Regional Pain Syndrome Type I (RSD) under High-Dose Intravenous Ketamine-Midazolam Sedation. 54th Annual Meeting of the American Academy of Neurology, AAN 2002 abstract #652450.

Kiefer RT, Rohr P, Ploppa A, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. *Pain Med.* 2008;9:1173-1201.

Kim M, Cho S, Lee JH. The effects of long-term ketamine treatment on cognitive function in complex regional pain syndrome: A preliminary study. *Pain Med*. 2016;17(8):1447-1451.

Kimura T, Komatsu T, Hosoda R, et al. Angiotensin-converting enzyme gene polymorphism in patients with neuropathic pain. In: Devor M, Rowbotham M, Wiesenfeld-Hallin D, eds. *Proceedings of the 9th World Conference on Pain*. Vol. 16. Seattle: IASP Press; 2000;471-476.

Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. *Pain*. 1997;73:123-139.

Korpan MI, Dezu Y, Schneider B, et al. Acupuncture in the treatment of posttraumatic pain syndrome. *Acta Orthop Belg*. 1999; 65:197-201.

Koulousakis A, Kuchta J, Bayarassou A, et al. Intrathecal opioids for intractable pain syndromes. *Acta Neurochir*. Suppl. 2007;97(Pt 1):43-48.

Kosharskyy B, Almonte W, Shaparin N, et al. Comprehensive Review. Intravenous infusions in chronic pain management. *Pain Physician*. 2013;16:231-239.

Kumar K, Bodani V, Bishop S, et al. Use of intrathecal bupivacaine in refractory chronic nonmalignant pain. *Pain Med*. 2009;10:819-828.

Kvarnstrom A, Karlsten R, Quiding H, et al. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. *Acta Anaesthesiol Scand*. 2003;47(7):868-877.

Lamer TJ, Deer TR, Hayek SM. Advanced innovations for pain. *Mayo Clin Proc*. 2016;91:246-258.

Lee SK, Yang DS, Lee JW, et al. Four treatment strategies for complex regional pain syndrome type I. *Orthopedics*. 2012;35:e834-842.

Livingstone JA, Atkins RM. Intravenous regional guanethidine blockade in the treatment of post-traumatic complex regional pain syndrome type 1 (algodystrophy) of the hand. *J Bone Joint Surg [Br]*. 2002;84-B:380-386.

Livingstone JA, Field J. Algodystrophy and its association with Dupuytren's disease. *J Hand Surg [Br]*. 1999;24:199-202.

Mackey S, Feinberg S. Pharmacologic therapies for complex regional pain syndrome. *Curr Pain Headache Rep*. 2007;11:38-43.

Mailis A, Wade JA. Genetic considerations in CRPS. In: Harden RN, Baron R, Janig W, eds. *Complex Regional Pain Syndrome*. IASP Press;2001;22:227-238.

Maillefert JF, Chatard C, Owens S, et al. Treatment of refractory reflex sympathetic dystrophy with pamidronate. *Ann Rheum Dis*. 1995;54:687.

Malik VK, Inchiosa M, Mustafa K, et al. Intravenous regional phenoxybenzamine in the treatment of reflex sympathetic dystrophy. *Anesthesiology*. 1998;88(3):823-827.

Meier PM, Zurakowski D, Berde CB, et al. Lumbar sympathetic blockade in children with complex regional pain syndromes: a double blind placebo-controlled crossover trial. *Anesthesiology*. 2009;111:372-380.

McLachlan EM, Janig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. *Nature*. 1993;363:543-546.

Merskey H, Bogduk N. *Classification of Chronic Pain: Description of Chronic Pain Syndromes and Definitions of Pain Terms*. 2nd ed. Seattle: IASP Press; 1994.

Mironer YE, Haasis JC, Chapple I, et al. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: A double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians. (NFIPC). *Neuromodulation*. 2002;5:208-213.

- Mittal SO, Safarpour D, Jabbari B. Botulinum toxin treatment of neuropathic pain. *Semin Neurol*. 2016;36:73-83.
- Munts AG, van der Plas AA, Voormolen JH, et al. Intrathecal glycine for pain and dystonia in complex regional pain syndrome. *Pain*. 2009;146:199-204.
- Munts AG, van der Plas AA, Ferrari MD, et al. Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome. *Eur J Pain*. 2010;14:523-528.
- National Institutes of Neurological Disorders and Stroke Website. Complex regional pain syndrome fact sheet. 05/2026. Available at: <https://www.ninds.nih.gov/health-information/disorders/complex-regional-pain-syndrome>. Accessed May 26, 2026.
- Nelson DV, Stacey BR. Interventional therapies in the management of complex regional pain syndrome. *Clin J Pain*. 2006;22:438-442.
- Noridian Medicare Local Coverage Determination (LCD): External Infusion Pump. L33794. Original 10/01/15. Revised 01/25/2026. Available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33794>. Accessed May 26, 2026.
- Noppers IM, Niesters M, Aarts LP, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type I patients: a report of 3 cases. *Pain*. 2011;152:1273-2178.
- Oaklander AL, Horowitz SH. The complex regional pain syndrome. *Handb Clin Neurol*. 2015;131:481-503.
- O'Connell NE, Wand BM, McAuley J, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome [review]. *Cochrane Database Syst Rev*. 2013;4:CD009416.
- O'Connell NE, Wand B, Gibson W, et al. Local anaesthetic sympathetic blockade for complex regional pain syndrome. *Cochrane Database Syst Rev*. 2016; 7(7):CD004598.
- Oh HM, Chung ME. Botulinum toxin for neuropathic pain: A review of the literature. *Toxins*. 2015;7:3127-3154.
- Oyen WJ, Arntz IE, Claessens RM, et al. Reflex sympathetic dystrophy of the pathogenesis of reflex sympathetic dystrophy? *Free Radic Res Commun*. 1987;3:13-18.
- Paraskevas KI, Michaloglou AA, Briana DD, et al. Treatment of complex regional pain syndrome type I of the hand with a series of intravenous regional sympathetic blocks with guanethidine and lidocaine. *Clin Rheumatol*. 2006;25:687-693.
- Park SY, Nahm FS, Kim YC, et al. The cut-off rate of skin temperature change to confirm successful lumbar sympathetic block. *J Int Med Res*. 2010;38(1):266-275.
- Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5 year retrospective analysis. *Pain Med*. 2013;13:263-269.
- Perez RS, Pragt E, Geurts J, et al. Treatment of patients with complex regional pain syndrome type I with mannitol: a prospective, randomized, placebo-controlled, double blinded study. *J Pain*. 2008;9:678-686.
- Perez RS, Zollinger PE, Dijkstra PU, et al. Evidence based guidelines for complex regional pain syndrome type 1. *BMC Neurol*. 2010;31:20.
- Pickering AE, McCabe CS. Prolonged ketamine infusion as a therapy for Complex Regional Pain Syndrome: Synergism with antagonism? *Br J Clin Pharmacol*. 2014;77(2):233-238.
- Plewes LW. Sudeck's atrophy in the hand. *J Bone Joint Surg Br*. 1956;38:195-203.
- Price DD, Long S, Wilsey B, Rath A. Analysis of peak magnitude and duration of analgesia produced by local anesthetics injected into sympathetic ganglia of complex regional pain syndrome patients. *Clin J Pain*. 1998;14:216-226.
- Procacci P, Francini F, Maresca M, Zoppi M. Skin potential and EMG changes induced by cutaneous electrical stimulation. II. Subjects with reflex sympathetic dystrophies. *Appl Neurophysiol*. 1979;42:125-134.

Puchalski P, Zyluk A. Results of the treatment of chronic, refractory CRPS with ketamine infusions? A preliminary report. *Handchir Mikrochir Plast Chir*. 2016;48:143-147.

Ramamurthy S, Hoffman J. Intravenous regional guanethidine in the treatment of reflex sympathetic dystrophy/causalgia: a randomized, double-blind study. Guanethidine Study Group. *Anesth Analg*. 1995;81:718-723.

Rauck RL, Eisenach JC, Jackson K, et al. Epidural clonidine treatment for refractory reflex sympathetic dystrophy. *Anesthesiology*. 1993;79:1163-1169, discussion 27A.

Rauck RL, North J, Eisenach JC. Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome. *Pain*. 2015;156:88-95.

Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. *J Pain Symptom Manag*. 2006;31:393-406.

Rawicki B, Sheean G, Fung VS, et al. Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement. *Eur J Neurol*. 2010;17(Suppl 2):122-134.

Resmini G, Ratti C, Canton g, et al. Treatment of complex regional pain syndrome. *Clin Cases Miner Bone Metab*. 2015 Jan-Apr;12(Suppl 1):26-30.

Rijsdijk M, van Wijck AJ, Kalkman CJ, et al. The effects of glucocorticoids on neuropathic pain: a review with emphasis on intrathecal methylprednisolone acetate delivery. *Anesth Analg*. 2014;118:1097-1112.

Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type I. *Pain Med*. 2004;5:276-280.

Rocco AG, Kaul AF, Reisman RM, et al. A comparison of regional intravenous guanethidine and reserpine in reflex sympathetic dystrophy. A controlled, randomized, double-blind crossover study. *Clin J Pain*. 1989;5:205-209.

Rockett M. Diagnosis, mechanisms and treatment of complex regional pain syndrome. *Curr Opin Anaesthesiol*. 2014;27:494-500.

Rodriguez MJ, Fernandez-Baena M, Barroso A, et al. Invasive management for pediatric complex regional pain syndrome: Literature review of evidence. *Pain Physician*. 2015;18:621-630.

Rosenberg JM, Harrell C, Ristie H, et al. The effect of gabapentin on neuropathic pain. *Clin J Pain*. 1997;15:251-255.

Rowbotham M, Wiesenfeld-Hallin D, eds. *Procedures of the 9th World Conference on Pain*. Vol. 16. Scavengers. *Unfallchirurg*. 1985;88:330-332.

Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *JAMA*. 1998;280:1837-1842.

Safarpour D, Salardini A, Richardson D, et al. Botulinum toxin for treatment of allodynia of complex regional pain syndrome: A pilot study. *Pain Med*. 2010;11:1411-1414.

Samen CDK, Sutton OM, Rice AE, et al. Correlation Between Temperature Rise After Sympathetic Block and Pain Relief in Patients with Complex Regional Pain Syndrome. *Pain Med*. 2022 Sep 30;23(10):1679-1689

Sawynok J. Topical and peripheral ketamine as an analgesic. *Anesth Analg*. 2014;119:170-178.

Schott GD. Reflex sympathetic dystrophy. *J Neurol Neurosurg Psychiatry*. 2001;71:291-295.

Schott GD. Bisphosphonates for pain relief in reflex sympathetic dystrophy? *Lancet*. 1997;350:1117.

Schwartzmann RJ. New treatments for reflex sympathetic dystrophy. *N Eng J Med*. 2000;343:654-656.

Schwartzman RJ, Alexander GM, Grothusen JR, et al. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. *Pain*. 2009;147:107-115.

- Schwartzman RJ, Alexander GM, Grothusen JR. The use of ketamine in complex regional pain syndrome: possible mechanisms. *Expert Rev Neurother*. 2011 May;11(5):719-34.
- Schwartzman RJ, Patel M, Grothusen JR, et al. Efficacy of 5-day continuous lidocaine infusion for the treatment of refractory complex regional pain syndrome. *Pain Med*. 2009;10:401-412.
- Sheehy KA, Muller EA, Lippold C, et al. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. *BMC Pediatr*. 2015;15:198.
- Shenoda BB, Alexander GM, Ajit SK. Has-miR-34a mediated repression of corticotrophin releasing hormone receptor 1 regulates pro-opiomelanocortin expression in patients with complex regional pain syndrome. *J Transl Med*. 2016;14:64.
- Sigtermans MJ, van Hilten JJ, Bauer MCR, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type I. *Pain*. 2009;145:304-311.
- Singh MK, Patel J, Grothusen J, et al. Physical Medicine and Rehabilitation for Complex Regional Pain Syndromes Treatment & Management. eMedicine website. 05/17/2017. Available at: <https://rds.org/wp-content/uploads/2017/05/Physical-Medicine-Rehabilitation-crps.pdf>. Accessed May 26, 2026.
- Stanton TR, Wand BM, Carr DB, et al. Local anaesthetic sympathetic blockade for complex regional pain syndrome. *Cochrane Database Syst Rev*. 2013;19:8:CD004598.
- Stanton-Hicks M, Baron R, Boas R, et al. Consensus report: complex regional pain syndromes: guidelines for therapy. *Clin J Pain*. 1998;14:155-166.
- Stanton-Hicks M, Jänig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. *Pain*. 1995;63-1:127-133.
- Stanton-Hicks M, Janig W, Hassenbusch S, et al. Reflex sympathetic dystrophy. *J Bone Joint Surg [Br]*. 1995;77-B:270-3.
- Straube S, Derry S, Moore RA, et al. Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. *Cochrane Database Syst Rev*. 2013 Sep 2;9:CD002918.
- Subbarao J, Stillwell GK. Reflex sympathetic dystrophy syndrome of the upper extremity: analysis of total outcome of management of 125 cases. *Arch Phys Med Rehabil*. 1981;62:549-554.
- Tajerian M, Clark JD. New concepts in complex regional pain syndrome. *Hand Clin*. 2016;32:41-44.
- Takahashi H, Miyazaki M, Nanbu T, et al. The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case. *Pain*. 1998;75:391-394.
- Taskaynatan MA, Ozgul A, Tan AK, et al. Bier block with methylprednisolone and lidocaine in CRPS type I: a randomized double-blinded, placebo-controlled study. *Reg Anesth Pain Med*. 2004;29:408-412.
- Toshniwal G, Sunder R, Thomas R, et al. Management of complex regional pain syndrome type I in upper extremity evaluation of continuous stellate ganglion block and continuous infraclavicular brachial plexus block: a pilot study. *Pain Med*. 2012;13:96-106.
- Tran DQ, Duong S, Bertini P, et al. Treatment of complex regional pain syndrome: a review of the evidence. *Can J Anaesth*. 2010;57:149-66.
- Turner-Stokes L, Goebel A: Guidance Development Group. Complex regional pain syndrome in adults: concise guidance. *Clin Med*. 2011;11:596-600.
- Uher EM, Vacariu G, Schneider B, Fialka V. Comparison of manual lymph drainage with physical therapy in complex regional pain syndrome, type I. A comparative randomized controlled therapy study. *Wien Klin Wochenschr*. 2000;112:133-137.
- van Hilten BJ, van de Beek, WT, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. *N Engl J Med*. 2000;343(9):625-630.

Van Daele PLA. Pamidronate in complex regional pain syndrome: effective therapy in CRPS. Editorial. *Neth J Med*. 2016;74:3-4.

van der Laan L, Goris RJ. Reflex sympathetic dystrophy: an exaggerated regional inflammatory response? *Hand Clin*. 1997;13:373-85.

van der Laan L, ter Laak HJ, Gabreels-Festen A, et al. Complex regional pain syndrome type 1 (RSD): pathology of skeletal muscle and peripheral nerve. *Neurology*. 1998;51:20-25.

van der Laan L, Kapitein P, Verhofstad A, et al. Clinical signs and symptoms of acute reflex sympathetic dystrophy in one hind limb of the rat, induced by infusion of a free-radical donor. *Acta Orthop Belg*. 1998;64:210-217.

van der Plas AA, Marinus J, Eldabe S, et al. The lack of efficacy of different infusion rates of intrathecal baclofen in complex regional pain syndrome: a randomized, double-blind, crossover study. *Pain Med*. 2011;12:459-465.

Van der Plas AA, Schilder JC, Marinus J, et al. An explanatory study evaluating the muscle relaxant effects of intramuscular magnesium sulphate for dystonia in complex regional pain syndrome. *J Pain*. 2013;14:341-348.

Van der Plas AA, van Rijn MA, Marinus J, et al. Efficacy of intrathecal baclofen on different pain qualities in complex regional pain syndrome. *Anesth Analg*. 2013;116:211-215.

Van Eijs F, Stanton-Hicks M, Van Zundert J, et al. Evidence-based interventional pain medicine according to clinical diagnoses. 16. Complex regional pain syndrome. *Pain Pract*. 2011;11:70-87.

Van Rijn MA, Munts AG, Marinus J, et al. Intrathecal baclofen for dystonia of complex regional pain syndrome. *Pain*. 2009;143:41-47.

Varenna M, Adami S, Rossini M, et al. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. *Rheumatology (Oxford)*. 2013;52:534-542.

Varenna M, Adami S, Sinigaglia L. Bisphosphonates in complex regional pain syndrome type I how do they work? *Clin Exp Rheumatol*. 2014;32:451-454.

Varenna M, Zucchi F, Ghiringhelli D, et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. *J Rheumatol*. 2000;27:1477-1483.

Varitimidis, SE, Papatheodorou LK, Dailiana ZR, et al. Complex regional pain syndrome type I as a consequence of trauma or surgery to upper extremity: management with intravenous regional anesthesia, using lidocaine and methylprednisolone. *J Hand Surg Eur*. Vol. 2011;36:771-777.

Veizi IE, Hayek SM, Narouze S, et al. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. *Pain Med*. 2011;12:1481-1489.

Veldman PH, Reynen HM, Arntz IE: Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. *Lancet*. 1993;342(8878):1012-1016.

Verdugo RJ, Ochoa JL. Sympathetically maintained pain. I. Phentolamine block questions the concept. *Neurology*. 1994;44:1003-1010.

Wahren LK, Gordh TJ, Torebjörk E. Effects of regional intravenous guanethidine in patients with neuralgia in the hand: a follow-up study over a decade. *Pain*. 1995;62:379-385.

Walker SM, Cousins MJ. Complex regional pain syndromes: including "reflex sympathetic dystrophy" and "causalgia." *Anaesth Intensive Care*. 1997;25(2):113-125.

Wall PD, Devor M. Sensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured rats. *Pain*. 1983;17:321-339.

Wall PD. Noradrenaline evokes pain in neuralgia. *Pain*. 1995;63:1-2.

Wallace MS, Ridgeway BM, Leung AY, et al. Concentration-effect relationship of intravenous lidocaine on the

allodynia of complex regional pain syndrome types I and II. *Anesthesiology*. 2000; 92:75-83.

Wallace MS, Rauck R, Fisher R, et al. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. *Anesth Analg*. 2008;106:628-637.

Wallace MS, Kosek PS, Staats P, et al. Phase II open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. *Pain Med*. 2008;9:271-281.

Washington State Department of Labor and Industries. Complex Regional Pain Syndrome (CRPS). Olympia (WA): Washington State Department of Labor and Industries. 1999, Jun. 9 p. [1 reference].

Washington State Department of Labor and Industries. Complex regional pain syndrome (CRPS). Medical Treatment Guidelines. Olympia, WA: Washington State Department of Labor and Industries; August 2002.

Washington State Department of Labor and Industries. Work-related complex regional pain syndrome (CRPS): Diagnosis and treatment. Original 10/01/2011. Updated 09/2016. Available at: https://lni.wa.gov/patient-care/treating-patients/treatment-guidelines-and-resources/_docs/Complexregionalpain.pdf. Accessed May 26, 2026.

Webster LR, Fisher R, Charapata S, et al. Long-term intrathecal ziconotide for chronic pain: an open-label study. *J Pain Symptom Manage*. 2009;37:363-372.

Wertli MM, Kessels AG, Perez RS, et al. Rational pain management in complex regional pain syndrome 1 (CRPS1) – A network meta-analysis. *Pain Med*. 2014;15:1575-1589.

Weissmann R, Uziel Y. Pediatric complex regional pain syndrome: a review. *Pediatr Rheumatol Online J*. 2016;14(1):29.

Wie C, Gupta R, Maloney J, Pew S, Freeman J, Strand N. Interventional Modalities to Treat Complex Regional Pain Syndrome. *Curr Pain Headache Rep*. 2021;25(2):10.

Williams G, Howard R. The pharmacological management of complex regional pain syndrome in pediatric patients. *Pediatr Drugs*. 2016;18:243-250.

Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms and management. *Lancet*. 1999;353:1959-1564.

Woolf CP, Doubell TP. The pathophysiology of chronic pain increased sensitivity to low threshold A beta-fiber inputs. *Curr Opin Neurobiol*. 1994;4:525-534.

Woolf CP, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. *Nature*. 1992;355:75-78.

Wu WH, Bandilla E, Ciccone DS, et al. Effects of qigong on late-stage complex regional pain syndrome. *Altern Ther Health Med*. 1999;5:45-54.

Xu J, Yang J, Lin P, et al. Intravenous therapies for complex regional pain syndrome: A systematic review. *Anesth Analg*. 2016;122:843-856.

Yucel I, Demiraran Y, Ozturan K, et al. Complex regional pain syndrome type I: efficacy of stellate ganglion blockade. *J Orthopaed Traumatol*. 2009;10:179-183.

Zernikow B, Wagner J, Brehmer H, et al. Invasive treatments for complex regional pain syndrome in children and adolescents: a scoping review. *Anesthesiology*. 2015;122:699-707.

Zollinger PE, Tuinebreijer WE, Kreis RW, Breederveld RS. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. *Lancet*. 1999;354:2025-2028.

Zuurmond WW, Langendijk PN, Bezemer PD, et al. Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream. *Acta Anaesthesiol Scand*. 1996;40:364-367.

Coding

Inclusion of a code in this table does not imply reimbursement. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

The codes listed below are updated on a regular basis, in accordance with nationally accepted coding guidelines. Therefore, this policy applies to any and all future applicable coding changes, revisions, or updates.

In order to ensure optimal reimbursement, all health care services, devices, and pharmaceuticals should be reported using the billing codes and modifiers that most accurately represent the services rendered, unless otherwise directed by the Company.

The Coding Table lists any CPT, ICD-10, and HCPCS billing codes related only to the specific policy in which they appear.

CPT Procedure Code Number(s)

MEDICALLY NECESSARY

POSTEPIDURAL CONTINUOUS PAIN MANAGEMENT CARE

01996

STELLATE GANGLION BLOCK (SGB)

64510

LUMBAR SYMPATHETIC BLOCK/IVRB

64520

EPIDURAL INFUSION

62324, 62325, 62326, 62327

CATHETER IMPLANTATION/REMOVAL (EPIDURAL OR INTRATHECAL)

62350, 62351, 62355

EPIDURAL RESERVOIR/PUMP IMPLANTATION (EPIDURAL OR INTRATHECAL) AND ELECTRONIC ANALYSIS

62360, 62361, 62362, 62365, 62367, 62368, 62369, 62370, 95990, 95991

EXPERIMENTAL/INVESTIGATIONAL FOR CRPS

36514, 36516, 64415, 64416, 64450, 64520

THE FOLLOWING CODE IS USED TO REPRESENT INJECTION, ANESTHETIC AGENT; CERVICAL, LUMBAR AND/OR SACRAL PLEXUS.

64999

ICD - 10 Procedure Code Number(s)

N/A

ICD - 10 Diagnosis Code Number(s)

G56.40 Causalgia of unspecified upper limb

G56.41 Causalgia of right upper limb

G56.42 Causalgia of left upper limb

G56.43 Causalgia of bilateral upper limbs

G57.70 Causalgia of unspecified lower limb

G57.71 Causalgia of right lower limb

G57.72 Causalgia of left lower limb

G57.73 Causalgia of bilateral lower limbs

G90.50 Complex regional pain syndrome I, unspecified

G90.511 Complex regional pain syndrome I of right upper limb

G90.512 Complex regional pain syndrome I of left upper limb

G90.513 Complex regional pain syndrome I of upper limb, bilateral

G90.519 Complex regional pain syndrome I of unspecified upper limb

G90.521 Complex regional pain syndrome I of right lower limb

G90.522 Complex regional pain syndrome I of left lower limb

G90.523 Complex regional pain syndrome I of lower limb, bilateral

G90.529 Complex regional pain syndrome I of unspecified lower limb

G90.59 Complex regional pain syndrome I of other specified site

M89.00 Algoneurodystrophy, unspecified site

M89.011 Algoneurodystrophy, right shoulder

M89.012 Algoneurodystrophy, left shoulder

M89.019 Algoneurodystrophy, unspecified shoulder

M89.021 Algoneurodystrophy, right upper arm

M89.022 Algoneurodystrophy, left upper arm

M89.029 Algoneurodystrophy, unspecified upper arm

M89.031 Algoneurodystrophy, right forearm

M89.032 Algoneurodystrophy, left forearm

M89.039 Algoneurodystrophy, unspecified forearm

M89.041 Algoneurodystrophy, right hand

M89.042 Algoneurodystrophy, left hand

M89.049 Algoneurodystrophy, unspecified hand

M89.051 Algoneurodystrophy, right thigh

M89.052 Algoneurodystrophy, left thigh
M89.059 Algoneurodystrophy, unspecified thigh
M89.061 Algoneurodystrophy, right lower leg
M89.062 Algoneurodystrophy, left lower leg
M89.069 Algoneurodystrophy, unspecified lower leg
M89.071 Algoneurodystrophy, right ankle and foot
M89.072 Algoneurodystrophy, left ankle and foot
M89.079 Algoneurodystrophy, unspecified ankle and foot
M89.08 Algoneurodystrophy, other site
M89.09 Algoneurodystrophy, multiple sites

HCPCS Level II Code Number(s)

THIS IS NOT AN ALL-INCLUSIVE LIST

C9812 Echogenic nerve block needles (e.g. sonoplex, sonoblock, sonotap), non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)

J0475 Injection, baclofen, 10 mg
J0476 Injection, baclofen, 50 mcg for intrathecal trial
J2278 Injection, ziconotide, 1 mcg
J2270 Injection, morphine sulfate, up to 10 mg
J2274 Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10mg
S0093 Injection, morphine sulfate, 500 mg (loading dose for infusion pump)

EXPERIMENTAL/INVESTIGATIONAL FOR CRPS

J0585 Injection, onabotulinumtoxinA, 1 unit
J0586 Injection, abobotulinumtoxinA, 5 units
J0587 Injection, rimabotulinumtoxinB, 100 units
J0588 Injection, incobotulinumtoxinA, 1 unit
J0665 Injection, bupivacaine, not otherwise specified, 0.5 mg
J0735 Injection, clonidine HCl, 1 mg
J1010 Injection, methylprednisolone acetate, 1 mg
J1212 Injection, DMSO, dimethyl sulfoxide, 50%, 50 ml
J1459 Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 mg

J1556 Injection, immune globulin (bivigam), 500 mg

J1557 Injection, immune globulin, (Gammaplex), intravenous, nonlyophilized (e.g., liquid), 500 mg

J1561 Injection, immune globulin, (Gamunex/Gamunex-C/Gammaked), nonlyophilized (e.g., liquid), 500 mg

J1566 Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg

J1568 Injection, immune globulin, (Octagam), intravenous, nonlyophilized (e.g., liquid), 500 mg

J1569 Injection, immune globulin, (gammagard liquid/gammagard liquid etc), non-lyophilized, (e.g., liquid), 500 mg

J1572 Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg

J1599 Injection, immune globulin, intravenous, nonlyophilized (e.g., liquid), not otherwise specified, 500 mg

J2002 Injection, lidocaine hcl in 5% dextrose, 1 mg

J2003 Injection, lidocaine hydrochloride, 1 mg

J2004 Injection, lidocaine hcl with epinephrine, 1 mg

J2151 Injection, mannitol, 250 mg

J2272 Injection, morphine sulfate (fresenius kabi) not therapeutically equivalent to j2270, up to 10 mg

J2760 Injection, phentolamine mesylate, up to 5 mg

J2919 Injection, methylprednisolone sodium succinate, 5 mg

J3475 Injection, magnesium sulfate, per 500 mg

THE FOLLOWING CODE REPRESENTS BISPHOSPHONATES, BRETYLIUM, DEXMEDETOMIDINE, GLYCINE, GUANETHIDINE, KETAMINE, KETANSERIN, PHENOXYBENZAMINE, AND RESERPINE:

J3490 Unclassified drugs

Revenue Code Number(s)

N/A

Coding And Billing Requirements

BILLING REQUIREMENTS

Inclusion of a code in this policy does not imply reimbursement. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

If there is no specific HCPCS code available for the drug administered, then the drug must be reported with the most appropriate unlisted code along with the corresponding National Drug Code (NDC).

Policy History

Revisions From MA08.026n+o:

09/18/2026	The policy has been updated to incorporate additional criteria requiring demonstration of the benefits from prior sympathetic nerve blocks.
------------	---

	This policy has been identified for the HCPCS code update, effective 09/18/2026. The following HCPCS narrative has been revised in this policy: J1569 FROM: Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg TO: Injection, immune globulin, (gammagard liquid/gammagard liquid erc), non-lyophilized, (e.g., liquid), 500 mg
--	--

Revisions From MA08.026m:

03/20/2026	Inclusion of a policy in a Code Update memo does not imply that a full review of the policy was completed at this time. This policy has been identified for the CPT code update, effective 03/20/2026. The following HCPCS code has been added to this policy: C9812 Echogenic nerve block needles (e.g. sonoplex, sonoblock, sonotap), non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023) The following HCPCS code has been deleted from this policy: J1572 Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg Note: In accordance with the CMS - Revised 2026 HCPCS Code Update - January Edition - Correct Coding publication posted on their site on 12/31/2025 to communicate that the below HCPCS code remains effective, on 03/20/2026, the following code was added back to this policy: J1572 Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg
------------	--

Revisions From MA08.026l:

12/15/2025	This policy has been identified for the HCPCS code update, effective 12/15/2025. The following HCPCS code has been deleted from this policy: J2150 Injection, mannitol, 25% in 50 ml The following HCPCS codes have been added to this policy: J2151 Injection, mannitol, 250 mg
------------	---

Revisions From MA08.026k:

12/16/2024	This policy has been identified for the HCPCS code update, effective 12/16/2024. The following CPT code has been removed from this policy: J2001 Injection, lidocaine HCl for intravenous infusion, 10 mg The following CPT codes have been added to this policy: J2002 Injection, lidocaine hcl in 5% dextrose, 1 mg J2003 Injection, lidocaine hydrochloride, 1 mg J2004 Injection, lidocaine hcl with epinephrine, 1 mg
------------	---

Revisions From MA08.026j:

05/07/2024	This policy has been identified and updated for the HCPCS code update effective 05/07/2024. The following HCPCS codes have been added to the policy: Experimental/Investigational: • J1010 Injection, methylprednisolone acetate, 1 mg • J2919 Injection, methylprednisolone sodium succinate, 5 mg The following HCPCS codes have been removed from this policy: • J1020 Injection, methylprednisolone acetate, 20 mg • J1030 Injection, methylprednisolone acetate, 40 mg • J1040 Injection, methylprednisolone acetate, 80 mg
------------	--

Revisions From MA08.026i:

07/01/2023	This policy has been identified for the CPT code update, effective on 07/01/2023. The following CPT code S0020 has been deleted from this policy. The following CPT code J0665 has been added to this policy.
------------	---

Revisions from MA08.026g

09/28/2020	This version of the policy will become effective on 09/28/2020. This policy has been updated to communicate the Company's experimental/investigational position on treatment of complex regional pain syndrome (CRPS) with plexus catheter nerve block and continuous peripheral nerve block. This policy has been identified for the following code update: 64450 Injection, anesthetic agent; other peripheral nerve or branch 64520 Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic) THE FOLLOWING CODES ARE USED TO REPRESENT INJECTION, ANESTHETIC AGENT; CERVICAL, LUMBAR AND/OR SACRAL PLEXUS. 64999 Unlisted procedure, nervous system.
------------	---

Revisions from MA08.026f

05/20/2020	The policy has been reviewed and reissued to communicate the Company's continuing position on Treatments for Complex Regional Pain Syndrome (CRPS).
01/01/2020	This policy has been identified for the CPT code update, effective 01/01/2020. The following CPT code has been removed from this policy: 64413 The following CPT code has been added to this policy: 64450

MA08.026e

09/25/2019	This policy has been reissued in accordance with the Company's annual review process.
03/01/2018	This version of the policy will become effective on 03/01/2018. The title of this policy was changed from:Complex Regional Pain Syndrome (CRPS) Parenteral

	Treatments To: Treatments for Complex Regional Pain Syndrome (CRPS) Additional changes include: Up to a maximum of six (6) total local anesthetic sympathetic nerve blocks, i.e., stellate ganglion block for upper-extremity pain or lumbar sympathetic block for lower-extremity pain related to CRPS are considered medically necessary, and, therefore covered in a 12-month period when other criteria detailed in the policy are met.
--	---

MA08.026d

01/01/2018	CPT code update for this policy, effective 01/01/2018: The following CPT code has been removed from this policy: 36515 Therapeutic apheresis; with extracorporeal immunoadsorption and plasma reinfusion The following CPT narrative has been revised in this policy: 36516: FROM: Therapeutic apheresis; with extracorporeal selective adsorption or selective filtration and plasma reinfusion TO: Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion
------------	---

MA08.026c

05/17/2017	This policy was updated to communicate the coverage position of plasma exchange for the treatment of CRPS. The coverage criteria was clarified for epidural opioids and for intrathecal baclofen.
------------	---

MA08.026b

01/01/2017	This policy has been identified for the CPT code update, effective 01/01/2017. The following CPT codes have been deleted from this policy: 62318, 62319 The following CPT codes have been added to this policy: 62324, 62325, 62326, 62327
------------	---

MA08.026a

10/28/2016	This policy has been reissued in accordance with the Company's annual review process.
03/29/2016	This policy was updated to clarify new criteria for the Medical Necessity of intrathecal opioids and intrathecal baclofen. This policy was also updated to convey new coverage determinations as Experimental/Investigational for the following drugs/nerve blocks/procedures for the treatment of CRPS: chemical sympathectomy, continuous peripheral nerve block with any drug, intramuscular ketamine, intrathecal opioids in combination with bupivacaine or lidocaine, intravenous dexmedetomidine, intravenous dimethylsulfoxide (DMSO), intravenous opioids, plasmapheresis, plexus catheter nerve block with any drug. The experimental/investigational statement was revised from an all-inclusive list to a not all-inclusive list. Information regarding epidural infusions of opioids, intrathecal infusions of opioids and baclofen by implantable pumps is consistent with Medicare's coverage criteria.

MA08.026

01/01/2015	This is a new policy. 12/03/2014: While the policy was in notification, this policy was identified for the HCPCS code update, effective 01/01/2015. Inclusion of a policy in a Code Update memo does not imply that a full review of the policy was completed at this time. On 12/04/2014, this Notification was revised to include HCPCS coding updates, effective 01/01/2015. This policy has been identified for the HCPCS code update, effective 01/01/2015. The following HCPCS codes have been termed from this policy: J2271 Injection, morphine sulfate, 100 mg J2275 Injection, morphine sulfate (preservative-free sterile solution), per 10 mg Q9974 Injection, Morphine Sulfate, Preservation-Free For Epidural Or Intrathecal Use, 10 mg The following HCPCS code has been added to this policy: J2274 Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10mg
------------	--

Version Effective Date:
09/18/2026
Version Issued Date:
09/18/2026
Version Reissued Date:
N/A